GB2308121A - Human neuronal nicotinic acetylcholine receptor compositions and methods employing same - Google Patents

Description

HUMAN NEURONAL NICOTINIC ACETYLCHOLIRE RECEPTOR COMPOSITIONS AND METHODS EMPLOYING SAME This invention relates to nucleic acids encoding human neuronal nicotinic acetylcholine receptor protein subunits, as well as the proteins themselves. In particular, human neuronal nicotinic acetylcholine receptor ss-subunit-encoding nucleic acids, p-subunit proteins and combinations thereof with a-subunit encoding nucleic acids and a-subunit proteins are provided.

This application is a divisional application from GB Patent Application No 9503688.5 (WO 94/20617) filed 8th March 1994 directed to a-subunit encoding nucleic acids and a-subunit proteins.

Ligand-gated ion channels provide a means for communication between cells of the central nervous system. These channels convert a signal (e.g., a chemical referred to as a neurotransmitter) that is released by one cell into an electrical signal that propagates along a target cell membrane. A variety of neurotransmitters and neurotransmitter receptors exist in the central and peripheral nervous systems. Five families of ligand-gated receptors, including the nicotinic acetylcholine receptors (NAChRs) of neuromuscular and neuronal origins, have been identified (Stroud et al. (1990) Biochemistry 29:11009-11023).

There is, however, little understanding of the manner in which the variety of receptors generates different responses to neurotransmitters or to other modulating ligands in different regions of the nervous system.

The nicotinic acetylcholine receptors (NAChRs) are multisubunit protein of neuromuscular and neuronal origins. These receptors form ligand-gated ioss channels that mediate synaptic transmission between nerve and muscle and between neurons upon interaction with the neurotransmitter acetylcholine (ACh). Since various nicotinic acetylcholine receptor (NAChR) subunits exist, a variety of NAChR compositions (i.e., combinations of subunits) exist. The different NAChR compositions exhibit different specificities for various ligands and are thereby pharmacologically distinguishable.Thus, the nicotinic acetylcholine receptors expressed at the vertebrate neuromuscular junction in vertebrate sympathetic ganglia and in the vertebrate central nervous system have been distinguished on the basis of the effects of various ligands that bind to different NAChR compositions. For example, the elapid a-neurotoxins that block activation of nicotinic acetylcholine receptors at the neuromuscular junction do not block activation of some neuronal nicotinic acetylcholine receptors that are expressed on several different neuron-derived cell lines.

Muscle NAChR is a glycoprotein composed of five subunits with the stoichiometry afl(y or c)6. Each of the subunits has a mass of about 50-60 kilodaltons (kd) and is encoded by a different gene. The a/(y or c)6 complex forms functional receptors containing two ligand binding sites and a ligand-gated transmembrane channel. Upon interaction with a cholinergic agonist, muscle nicotinic AChRs conduct sodium ions. The influx of sodium ions rapidly short-circuits the normal ionic gradient maintained across the plasma membrane, thereby depolarizing the membrane. By reducing the potential difference across the membrane, a chemical signal is transduced into an electrical signal that signals muscle contraction at the neuromuscular junction.

Functional muscle nicotinic acetylcholine receptors have been formed with ag6y subunits, afly subunits, aS6 subunits, a6y subunits or a6 subunits, but not with only one subunit (see e.g., Kurosaki et al.

(1987) FEBS Lett. 214: 253-258; Camacho et al. (1993) J.

Neuroscience 13:605-613). In contrast, functional neuronal AChRs (nAChRs) can be formed from a subunits alone or combinations of a and ss subunits. The larger a subunit is generally believed to be the Ach-binding subunit and the lower molecular weight ss subunit is generally believed to be the structural subunit, although it has not been definitively demonstrated that the ss subunit does not have the ability to bind ACh. Each of the subunits which participate in the formation of a functional ion channel are, to the extent they contribute to the structure of the resulting channel, "structural" subunits, regardless of their ability (or inability) to bind ACh.Neuronal AChRs (nAChRs), which are also ligand-gated ion channels, are expressed in ganglia of the autonomic nervous system and in the central nervous system (where they mediate signal transmission), in postsynaptic locations (where they modulate transmission), and in pre- and extra-synaptic locations (where they may have additional functions).

Nucleic acids encoding NAChRs has been isolated from several sources. Based on the information available from such work, it has been evident for some time that NAChRs expressed in muscle, in autonomic ganglia, and in the central nervous system are functionally diverse.

This functional diversity could be due, at least in part, to the large number of different NAChR subunits which exist. There is an incomplete understanding, however, of how (and which) NAChR subunits combine to generate unique NAChR subtypes, particularly in neuronal cells. Indeed, there is evidence that only certain NAChR subtypes may be involved in diseases such as Alzheimer's disease.

Moreover, it is not clear whether NAChRs from analogous tissues or cell types are similar across species.

Accordingly, there is a need for the isolation and characterization of nucleic acids encoding each human neuronal NAChR subunit, recombinant cells containing such subunits and receptors prepared therefrom. In order to study the function of human neuronal AChRs and to obtain disease-specific pharmacologically active agents, there is also a need to obtain isolated (preferably purified) human neuronal nicotinic AChRs, and isolated (preferably purified) human neuronal nicotinic AChR subunits. In addition, there is also a need to develop assays to identify such pharmacologically active agents.

The availability of such nucleic acids, cells, receptor subunits and receptor compositions will eliminate the uncertainty of speculating as to human nNAChR structure and function based on predictions drawn from non-human nNAChR data, or human or non-human muscle or ganglia NAChR data.

Therefore, it is an object herein to isolate and characterize nucleic acids encoding subunits of human neuronal nicotinic acetylcholine receptors. It is also an object herein to provide methods for recombinant production of human neuronal nicotinic acetylcholine receptor subunits. It is also an object herein to provide purified receptor subunits and to provide methods for screening compounds to identify compounds that modulate the activity of human neuronal AChRs.

These and other objects will become apparent to those of skill in the art upon further study of the specification and claims.

BRIEF DESCRIPTION OF THE INVENTION In accordance with the present invention, there are provided isolated nucleic acids encoding novel human beta subunits of neuronal NAChRs. In particular, isolated DNA encoding human ss4 subunits of neuronal NAChRs are provided. Messenger RNA and polypeptides encoded by the above-described nucleic acids are also provided.

Further in accordance with the present invention, there are provided recombinant human neuronal nicotinic AChR ss subunits, as well as methods for the production thereof.

In addition, recombinant human neuronal nicotinic acetylcholine receptors containing at least one human neuronal nicotinic AchR subunit including ss4 are also provided, as well as methods for the production thereof. Further provided are recombinant neuronal nicotinic AChRs that contain a mixture of one or more NAChR subunits encoded by a host cell, and one or more nNAChR subunits encoded by heterologous DNA or RNA (i.e., DNA or RNA as described herein that has been introduced into the host cell), as well as methods for the production thereof.

Plasmids containing DNA encoding the abovedescribed subunits are also provided. Recombinant cells containing the above-described DNA, mRNA or plasmids are also provided herein. Such cells are useful, for example, for replicating DNA, for producing human NAChR subunits and recombinant receptors, and for producing cells that express receptors containing one or more human subunits.

Also provided in accordance with the present invention are methods for identifying cells that express functional nicotinic acetylcholine receptors. Methods for identifying compounds which modulate the activity of NAChRs are also provided.

The DNA, mIlNA, vectors, receptor subunits, receptor subunit combinations and cells provided herein permit production of selected neuronal nicotinic AChR subunits and specific combinations thereof, as well as antibodies to said receptor subunits. This provides a means to prepare synthetic or recombinant receptors and receptor subunits that are substantially free of contamination from many other receptor proteins whose presence can interfere with analysis of a single NAChR subunit. The availability of desired receptor subunits makes it possible to observe the effect of a drug substance on a particular receptor subtype and to thereby perform initial in vitro screening of the drug substance in a test system that is specific for humans and specific for a human neuronal nicotinic AChR subtype.

The availability of subunit-specific antibodies makes possible the application of the technique of immunohistochemistry to monitor the distribution and expression density of various subunits (e.g., in normal vs diseased brain tissue). Such antibodies could also be employed for diagnostic and therapeutic applications.

The ability to screen drug substances in vitro to determine the effect of the drug on specific receptor compositions should permit the development and screening of receptor subtype-specific or disease-specific drugs.

Also, testing of single receptor subunits or specific receptor subunit combinations with a variety of potential agonists or antagonists provides additional information with respect to the function and activity of the individual subunits and should lead to the identification and design of compounds that are capable of very specific interaction with one or more receptor subtypes. The resulting drugs should exhibit fewer unwanted side effects than drugs identified by screening with cells that express a variety of subtypes.

Further in relation to drug development and therapeutic treatment of various disease states, the availability of nucleic acids encoding human nNAChR subunits enables identification of any alterations in such genes (e.g., mutations) which may correlate with the occurrence of certain disease states. In addition, the creation of animal models of such disease states becomes possible, by specifically introducing such mutations into synthetic DNA sequences which can then be introduced into laboratory animals or in vitro assay systems to determine the effects thereof.

BRIEF DESCRIPTION OF THE FIGURE Figure 1 presents a restriction map of two pCMV promoter-based vectors, pCMV-T7-2 and pCMV-T7-3.

DETAILED DESCRIPTION OF THE INVENTION In accordance with the present invention, we have isolated and characterized nucleic acids encoding novel human beta subunits of neuronal NAChRs.

Specifically, isolated DNAs encoding pal subunits of neuronal NAChRs are described herein.

Recombinant messenger RNA (mRNA) and recombinant polypeptides encoded by the above-described nucleic acids are also provided.

As used. herein, isolated (or substantially pure) as a modifier of DNA, RNA, polypeptides or proteins means that the DNA, RNA, polypeptides or proteins so designated have been separated from their in vivo cellular environments through the efforts of human beings. Thus as used herein, isolated (or substantially pure) DNA refers to DNAs purified according to standard techniques employed by those skilled in the art (see, e.g., Maniatis et al.(1982) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

Similarly, as used herein, "recombinant" as a modifier of DNA, RNA, polypeptides or proteins means that the DNA, RNA, polypeptides or proteins so designated have been prepared by the efforts of human beings, e.g., by cloning, recombinant expression, and the like. Thus as used herein, recombinant proteins, for example, refers to proteins produced by a recombinant host, expressing nucleic acidss which have been added to that host through the efforts of human beings.

As used herein, a human alpha subunit gene is a gene that encodes an alpha subunit of a human neuronal nicotinic acetylcholine receptor. The alpha subunit is a subunit of the NAChR to which Ach binds. Assignment of the name 'alpha" to a putative nNAChR subunit, according to Deneris et al. [Tips (1991) 12:34-40] is based on the conservation of adjacent cysteine residues in the presumed extracellular domain of the subunit that are the homologues of cysteines 192 and 193 of the Torpedo alpha subunit (see Noda et al. (1982) Nature 299:793-797). As used herein, an alpha subunit refers to a human nNAChR subunit that is encoded by nucleic acids that hybridizes under high stringency conditions to at least one of the nNAChR alpha subunit-encoding nucleic acidss (or deposited clones) disclosed herein. An alpha subunit also binds to ACh under physiological conditions and at physiological concentrations and, in the optional presence of a beta subunit (i.e., some alpha subunits are functional alone, while others require the presence of a beta subunit), generally forms a functional AChR as assessed by methods described herein or known to those of skill in this art.

Also contemplated are alpha subunits encoded by nucleic acids that encode alpha subunits as defined above, but that by virtue of degeneracy of the genetic code do not necessarily hybridize to the disclosed nucleic acids or deposited clones under specified hybridization conditions. Such subunits also participate in the formation of a functional receptor, as assessed by the methods described herein or known to those of skill in the art, generally with one or more beta subunits.

Typically, unless an alpha subunit is encoded by RNA that arises from alternative splicing (i.e., a splice variant), alpha-encoding nucleic acids and the alpha subunit encoded thereby share substantial sequence homology with at least one of the alpha subunit nucleic acidss (and proteins encoded thereby) described or deposited herein. It is understood that DNA or RNA encoding a splice variant may overall share less than 902 homology with the DNA or RNA provided herein, but include regions of nearly 100% homology to a DNA fragment or deposited clone described herein, and encode an open reading frame that includes start and stop codons and encodes a functional alpha subunit.

As used herein, a splice variant refers to variant NAChR subunit-encoding nucleic acid(s) produced by differential processing of primary transcript(s) of genomic DNA, resulting in the production of more than one type of raRNA. cDNA derived from differentially processed genomic DNA will encode NAChR subunits that have regions of complete amino acid identity and regions having different amino acid sequences. Thus, the same genomic sequence can lead to the production of multiple, related mRNAs and proteins. Both the resulting mRNAs and proteins are referred to herein as "splice variants1,.

Stringency of hybridization is used herein to refer to conditions under which polynucleic acid hybrids are stable. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature (Tm) of the hybrids. Tm can be approximated by the formula: 81.50C - 16.6(1Oql0[Na ]) + 0.41(%G+C) - 600/1, where 1 is the length.of the hybrids in nucleotides. T.

decreases approximately l-l.50C with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridization reaction is performed under conditions of lower stringency, followed by washes of varying, but higher, stringency. Reference to hybridization stringency relates to such washing conditions. Thus, as used herein: (1) HIGH STRINGENCY refers to conditions that permit hybridization of only those nucleic acid sequences that form stable hybrids in 0.018M NaCl at 650C (i.e., if a hybrid is not stable in 0.018M NaCl at 650C, it will not be stable under high stringency conditions, as contemplated herein).High stringency conditions can be provided, for example, by hybridization in 50% formamide, 5X Denhardt's solution, 5X SSPE, 0.2% SDS at 420C, followed by washing in 0.1X SSPE, and 0.1% SDS at 650C; (2) MODERATE STRINGENCY refers to conditions equivalent to hybridization in 50S formamide, 5X Denhardt's solution, 5X SSPE, 0.2% SDS at 42"C, followed by washing in 0.2X SSPE, 0.2% SDS, at 650C; and (3) LOW STRINGENCY refers to conditions equivalent to hybridization in 10% formamide, 5X Denhardt's solution, 6X SSPE, 0.2% SDS, followed by washing in 1X SSPE, 0.2t SDS, at 50tC.

It is understood that these conditions may be duplicated using a variety of buffers and temperatures and that they are not necessarily precise.

Denhardt's solution and SSPE (see, e.g., Sambrook, Fritsch, and Maniatis, in: Molecular Cloning.

A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989) are well known to those of skill in the art as are other suitable hybridization buffers. For example, SSPE is pH 7.4 phosphate-buffered 0.18M NaCl. SSPE can be prepared, for example, as a 20X stock solution by dissolving 175.3 g of NaCl, 27.6 g of NaH2PO4 and 7.4 g EDTA in 800 ml of water, adjusting the pH to 7.4, and then adding water to 1 liter. Denhardt's solution (see, Denhardt (1966) Biochem. Biophys. Res. Commun. 23:641) can be prepared, for example, as a 50X stock solution by mixing 5 g Ficoll (Type 400, Pharmacia LKB Biotechnology, INC., Piscataway NJ), 5 g of polyvinylpyrrolidone, 5 g bovine serum albumin (Fraction V; Sigma, St. Louis MO) water to 500 ml and filtering to remove particulate matter.

The phrase "substantial sequence homology" is used herein in reference to the nucleotide sequence of DNA, the ribonucleotide sequence of RNA, or the amino acid sequence of protein, that has slight and nonconsequential sequence variations from the actual sequences disclosed herein. Species having substantial sequence homology are considered to be equivalent to the disclosed sequences and as such are within the scope of the appended claims. In this regard, "slight and nonconsequential sequence variations" mean that "homologous" sequences, i.e., sequences that have substantial homology with the DNA, RNA, or proteins disclosed and claimed herein, are functionally equivalent to the sequences disclosed and claimed herein.Functionally equivalent sequences will function in substantially the same manner to produce substantially the same compositions as the nucleic acid and amino acid compositions disclosed and claimed herein. In particular, functionally equivalent nucleic acidss encode proteins that are the same as those disclosed herein or that have conservative amino acid variations, such as substitution of a non-polar residue for another non-polar residue or a charged residue for a similarly charged residue. These changes include those recognized by those of skill in the art as those that do not substantially alter the tertiary structure of the protein.

In practice, the term substantially the same sequence means that DNA or RNA encoding two proteins hybridize under conditions of high stringency and encode proteins that have the same sequence of amino acids or have changes in sequence that do not alter their structure or function. As used herein, substantially identical sequences of nucleotides share at least about 90% identity, and substantially identical amino acid sequences share more than 95% amino acid identity. It is recognized, however, that proteins (and DNA or mRNA encoding such proteins) containing less than the abovedescribed level of homology arising as splice variants or that are modified by conservative amino acid substitutions (or substitution of degenerate codons) are contemplated to be within the scope of the present invention.

As used herein, "an subunit DNA" refers to DNA encoding a neuronal nicotinic cetylcholine receptor subunit of the same name. Such DNA can be characterized in a number of ways, for example said DNA may encode the amino acid sequence set forth in SEQ. ID No. 6, or said DNA may encode the amino acid sequence encoded by clone HnAChRa4.2, deposited under ATCC Accession No. 69239, or the 5' nucleotides of said DNA may encode the amino acid sequence encoded by clone HnAChRa4.1, deposited under ATCC Accession No. 69152.

a,-encoding DNAs can be characterized as follows said DNA may hybridize to the coding sequence set forth in SEQ. ID No. 5 (preferably to substantially the entire coding sequence thereof, i.e., nucleotides 173-2056) under high stringency conditions, or said DNA may hybridize under high stringency conditions to the sequence (preferably to substantially the entire sequence) of the encoding insert of clone HnAChRa4.2, deposited under ATCC Accession No. 69239, or the 5' nucleotides of said DNA may hybridize under high stringency conditions to the sequence of the encoding insert of clone HnAChRa4.1, deposited under ATCC Accession No. 69152.

Especially preferred encoding DNAs are characterized as follows DNA having substantially the same nucleotide sequence as the coding region set forth in SEQ. ID No. 5 (i.e., nucleotides 173-2056 thereof), or DNA having substantially the same nucleotide sequence as the encoding insert of clone HnAChRa4.2, deposited under ATCC Accession No. 69239, or the 5' nucleotides of said DNA have substantially the same sequence as the encoding insert of clone HnAChRa4.1, deposited under ATCC Accession No.

69152.

Typically, unless an a4 subunit arises as a splice variant, encoding DNA will share substantial sequence homology (i.e., greater than about 90%), with the ar DNAs described or deposited herein. DNA or RNA encoding a splice variant may share less than 90% overall sequence homology with the DNA or RNA provided herein, but such a splice variant would include regions of nearly 100% homology to the above-described DNAs.

As used herein1 "a7 subunit DNA" refers to DNA encoding a neuronal nicotinic acetylcholine receptor subunit of the same name. Such DNA can be characterized in a number of ways, for example, the nucleotides of said DNA may encode the amino acid sequence set forth in SEQ.

ID No. 8. encoding DNAs can be characterized as DNA which hybridizes under high stringency conditions to the coding sequence set forth in SEQ. ID No. 7 (preferably to substantially the entire coding sequence thereof, i.e., nucleotides 73-1581).

Especially preferred a7-encoding DNAs are characterized as having substantially the same nucleotide sequence as the coding sequence set forth in SEQ. ID No.

7 (i.e., nucleotides 73-1581 thereof).

Typically unless an a7 subunit arises as a splice variant, a7-encoding DNA will share substantial sequence homology (greater than about 90%) with the a7 DNAs described or deposited herein. DNA or RNA encoding a splice variant may share less than 90% overall sequence homology with the DNA or RNA provided herein, but such DNA would include regions of nearly 100t homology to the above-described DNA.

The a7 subunits derived from the above-described DNA are expected to bind to the neurotoxin, a-bungarotoxin (a-bgtx). The activity of AChRs that contain a7 subunits should be inhibited upon interaction with a-bgtx. Amino acid residues 210 through 217, as set forth in SEQ ID No. 8, are believed to be important elements in the binding of a-bgtx (see, for example, Chargeaux et al. (1992) 13:299-301).

As used herein, a human beta subunit gene is a gene that encodes a beta subunit of a human neuronal nicotinic acetylcholine receptor. Assignment of the name "beta" to a putative nNAChR subunit, according to Deneris et al. supra, is based on the lack of adjacent cysteine residues (which are characteristic of alpha subunits).

The beta subunit is frequently referred to as the structural NAChR subunit (although it is possible that beta subunits also have ACh binding properties).

Combination of beta subunit(s) with appropriate alpha subunit(s) leads to the formation of a functional receptor. As used herein, a beta subunit refers to a nNAChR subunit that is encoded by DNA that hybridizes under high stringency conditions to at least one of the nNAChR-encoding DNAs (or deposited clones) disclosed herein. A beta subunit forms a functional NAChR, as assessed by methods described herein or known to those of skill in this art, with appropriate alpha subunit(s).

Also contemplated are beta subunits encoded by DNAs that encode beta subunits as defined above, but that by virtue of degeneracy of the genetic code do not necessarily hybridize to the disclosed DNA or deposited clones under the specified hybridization conditions.

Such subunits also form functional receptors, as assessed by the methods described herein or known to those of skill in the art, in combination with appropriate alpha subunit(s). Typically, unless a beta subunit is encoded by RNA that arises as a splice variant, beta-encoding DNA and the beta subunit encoded thereby share substantial sequence homology with the beta-encoding DNA and beta subunit protein described herein. It is understood that DNA or RNA encoding a splice variant may share less than 90t overall homology with the DNA or P4A provided herein, but such DNA will include regions of nearly 100% homology to the DNA described herein.

As used herein, 'ss subunit DNA" refers to DNA encoding a neuronal nicotinic acetylcholine receptor subunit of the same name. Such DNA can be characterized in a number of ways, for example, the nucleotides of said DNA may encode the amino acid sequence set forth in SEQ.

ID No. 12. Presently preferred ss4-encoding DNAs can be characterized as DNA which hybridizes under high stringency conditions to the coding sequence set forth in SEQ. ID No. 11 (preferably to substantially the entire coding sequence thereof, i.e., nucleotides 87-1583).

Especially preferred ss4-encoding DNAs of the invention are characterized as having substantially the same nucleotide sequence as set forth in SEQ. ID No. 11.

Typically, unless a 4 subunit arises as a splice variant, ss4-encoding DNA will share substantial sequence homology (greater than about 90%) with the ss DNAs described or deposited herein. DNA or RNA encoding a splice variant may share less than 90% overall sequence homology with the DNA or RNA provided herein, but such DNA would include regions of nearly 100% homology to the above-described DNA.

DNA encoding human neuronal nicotinic AChR alpha and beta subunits may be isolated by screening suitable human cDNA or human genomic libraries under suitable hybridization conditions with DNA disclosed herein (including nucleotides derived from any of SEQ ID Nos. 5, 7 or 11, or with any of the deposited clones referred to herein (e.g., ATCC accession no. 69239 or 69152). Suitable libraries can be prepared from neuronal tissue samples, hippocampus tissue, or cell lines, such as the human neuroblastoma cell line 1MR32 (ATCC Accession No. CCL127), and the like. The library is preferably screened with a portion of DNA including the entire subunit-encoding sequence thereof, or the library may be screened with a suitable probe.

As used herein, a probe is single-stranded DNA or RNA that has a sequence of nucleotides that includes at least 14 contiguous bases that are the same as (or the complement of) any 14 bases set forth in any of SEQ ID Nos. 1, 3, 5, 7, 9, or 11, or in the subunit encoding DNA in any of the deposited clones described herein (e.g., ATCC accession no. 69239 or 69152). Preferred regions from which to construct probes include 5' and/or 3' coding sequences, sequences predicted to encode transmembrane domains, sequences predicted to encode the cytoplasmic loop, signal sequences, acetylcholine (ACh) and a-bungarotoxin (a-bgtx) binding sites, and the like.

Amino acids 210-220 are typically involved in ACh and a-bgtx binding. The approximate amino acid residues which are predicted to comprise such regions for other preferred probes are set forth in the following table: Subunit Signal Seguence TMD1 TMD2 TMD3 TMD4 Cytoplasmic Loop α2 1-55 264-289 297-320 326-350 444-515 351-443 α3 1-30 240-265 273-296 302-326 459-480 327-458 α4 1-33 241-269 275-289 303-330 593-618 594-617 α7 1-23 229-256 262-284 290-317 462-487 318-461 ss2 1-25 234-259 267-288 295-320 453-477 321-452 ss4 1-23 234-258 264-285 290-319 454-478 320-453 * TMD = transmembrane domain Alternatively, portions of the DNA can be used as primers to amplify selected fragments in a particular library.

After screening the library, positive clones are identified by detecting a hybridization signal; the identified clones are characterized by restriction enzyme mapping and/or DNA sequence analysis, and then examined, by comparison with the sequences set forth herein or with the deposited clones described herein1 to ascertain whether they include DNA encoding a complete alpha or beta subunit. If the selected clones are incomplete, they may be used to rescreen the same or a different library to obtain overlapping clones. If desired, the library can be rescreened with positive clones until overlapping clones that encode an entire alpha or beta subunit are obtained. If the library is a cDNA library, then the overlapping clones will include an open reading frame. If the library is genomic1 then the overlapping clones may include exons and introns.In both instances, complete clones may be identified by comparison with the DNA and encoded proteins provided herein.

Complementary DNA clones encoding various human nNAChR alpha and beta subunits have been isolated. Each subunit appears to be encoded by a different gene. The DNA clones provided herein may be used to isolate genomic clones encoding each subunit and to isolate any splice variants by screening libraries prepared from different neural tissues. Nucleic acid amplification techniques, which are well known in the art, can be used to locate splice variants of human NAChR subunits. This is accomplished by employing oligonucleotides based on DNA sequences surrounding divergent sequence(s) as primers for amplifying human RNA or genomic DNA. Size and sequence determinations of the amplification products can reveal the existence of splice variants.Furthermore, isolation of human genomic DNA sequences by hybridization can yield DNA containing multiple exons, separated by introns, that correspond to different splice variants of transcripts encoding human NAChR subunits.

It has been found that not all subunits are expressed in all neural tissues or in all portions of the brain. Thus, in order to isolate cDNA encoding particular subunits or splice variants of such subunits, it is preferable to screen libraries prepared from different neuronal or neural tissues. Preferred libraries for obtaining DNA encoding each subunit include: hippocampus to isolate human 4- and a5-encoding DNA; IMR32 (human neuroblastoma cells; ATCC Accession No.

CCL127) to isolate human a3-, # a7- and ss4-encoding DNA, thalamus to isolate a2 and ss2-encoding DNA; and the like.

It appears that the distribution of expression of human neuronal nicotinic AChRs differs from the distribution of such receptors in rat. For example, RNA encoding the rat aX subunit is abundant in rat thalamus, but is not abundant in rat hippocampus (see, e.g., Wada et al. (1989) J. Comp. Neurol 284:314-335). No o,-encoding clones could be obtained, however, from a human thalamus library. Instead, human a, clones were ultimately obtained from a human hippocampus library.

Thus, the distribution of 4 nNAChR subunit in humans and rats appears to be quite different.

Rat a3 subunit appears to be a CNS-associated subunit that is abundantly expressed in the thalamus and weakly expressed in the brain stem (see, e.g., Boulter et al. (1986) Nature 319:368-374; Boulter et al. (1987) Proc. Natl. Acad. Sci. USA 84:7763-7767; and Wada et al.

(1989) J. Comp. Neurol 284:314-335). In efforts to clone DNA encoding the human nicotinic AChR a3 subunit, however, several human libraries, including a thalamus library, were unsuccessfully screened. Surprisingly, clones encoding human a3 subunit were ultimately obtained from a brain stem library and from IMR32 cells that reportedly express few, if any, functional nicotinic acetylcholine receptors (see, e.g., Gotti et al. ((1986) Biochem.

Biophys. Res. Commun. 137: 1141-1147, and Clementi et al. (1986) J. Neurochem. 47: 291-297).

Rat a7 subunit transcript reportedly is abundantly expressed in the hippocampus (see Seguela et al. (1993) J. Neurosci. 13:596-604). Efforts to clone DNA encoding a human α7 subunit from a human hippocampus library (1x106 recombinants) were unsuccessful.

Surprisingly, clones encoding a human NAChR a7 subunit were ultimately obtained from an IMR32 cell cDNA library.

The above-described nucleotide sequences can be incorporated into vectors for further manipulation. As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof.

Selection and use of such vehicles are well within the level of skill of the art.

As used herein, heterologous or foreign DNA and RNA are used interchangeably and refer to DNA or RNA that does not occur naturally as part of the genome of the cell in which it is present, or to DNA or RNA which is found in a location or locations in the genome that differ from that in which it occurs in nature.

Typically, heterologous or foreign DNA and RNA refers to DNA or RNA that is not endogenous to the host cell and has been artificially introduced into the cell. Examples of heterologous DNA include DNA that encodes a human neuronal nicotinic AChR subunit, DNA that encodes RNA or proteins that mediate or alter expression of endogenous DNA by affecting transcription, translation, or other regulatable biochemical processes, and the like. The cell that expresses heterologous DNA may contain DNA encoding the same or different expression products.

Heterologous DNA need not be expressed and may be integrated into the host cell genome or maintained episomally.

An expression vector includes vectors capable of expressing DNAs that are operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments.

Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned nucleic acids. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome. Presently preferred plasmids for expression of invention AChR subunits in eukaryotic host cells, particularly mammalian cells, include cytomegalovirus (CMV) promoter-containing vectors such as pCMV, pcDNAl, and the like, as well as MMTV promoter-containing vectors, such as pMAMneo, and the like.

As used herein, a promoter region refers to a segment of DNA that controls transcription of DNA to which it is operatively linked. The promoter region includes specific sequences that are sufficient for RNA polymerase recognition, binding and transcription initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region includes sequences that modulate this recognition, binding and transcription initiation activity of RNA polymerase. These sequences may be cis acting or may be responsive to trans acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated.Exemplary promoters contemplated for use in the practice of the present invention include the SV40 early promoter1 the cytomegalovirus (CMV) promoter, the mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, and the like.

As used herein, the term "operatively linked" refers to the functional relationship of nucleic acids with regulatory and effector sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences.

For example, operative linkage of nucleic acids to a promoter refers to the physical and functional relationship between the nucleic acids and the promoter such that the transcription of such nucleic acids is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the nucleic acids. In order to optimize expression and/or in vitro transcription, it may be necessary to remove or alter 5' and/or 3' untranslated portions of the clones to remove extra, potential alternative translation initiation (i.e., start) codons or other sequences that interfere with or reduce expression, either at the level of transcription or translation. Alternatively, consensus ribosome binding sites (see, for example, Kozak (1991) J. Biol. Chem. 266:19867-19870) can be inserted immediately 5' of the start codon to enhance expression.

Furthermore, for expression of NAChR subunits in amphibian oocytes, it may be desirable to surround the subunit coding sequence with Xenopus B-globin gene 5' and 3' untranslated sequences for optimum protein production.

For example, NAChR subunit coding sequences can be incorporated into vector pSP64T (see Krieg and Melton in Nucleic Acids Research 12:7057-7070 (1984)), a modified form of pSP64 (available from Promega, Madison, WI). The coding sequence is inserted between p-globin gene 5' and 3' untranslated sequences located downstream of the SP6 promoter. In vitro transcripts can then be generated from the resulting vector. The desirability of (or need for) such modification may be empirically determined.

Those of skill in the art recognize that a variety of promoters, enhancers, signal sequences, and the like can be employed to promote the expression of the cloned sequences described herein. In addition, it is readily recognized that the regulatory elements employed in a given construct need not be obtained from the same source. Indeed, the regulatory elements employed in a given construct can be obtained from different sources, such that various combinations of regulatory elements can be combined in a particular construct for expression.

As used herein, expression refers to the process by which polynucleic acids are transcribed into mRNA and translated into peptides, polypeptides, or proteins. If the polynucleic acid is derived from genomic DNA, expression may, if an appropriate eukaryotic host cell or organism is selected, include splicing of the mRNA.

Particularly preferred vectors for transfection of mammalian cells are the pSV2dhfr expression vectors, which contain the SV40 early promoter, mouse dhfr gene, SV40 polyadenylation and splice sites and sequences necessary for maintaining the vector in bacteria, cytomegalovirus (CMV) promoter-based vectors such as pCDNA1 (Invitrogen, San Diego, CA), and ~eTV promoterbased vectors such as pMAMneo (Clontech, Palo Alto, CA), and modifications thereof.

Full-length DNAs encoding human neuronal NAChR subunits have been inserted into vector pCMV-T7, a pUCl9- based mammalian cell expression vector containing the CMV promoter/enhancer, SV40 splice/donor sites located immediately downstream of the promoter, a polylinker downstream of the splice/donor sites, followed by an SV40 polyadenylation signal. Placement of NAChR subunit DNA between the CMV promoter and SV40 polyadenylation signal provides for constitutive expression of the foreign DNA in a mammalian host cell transfected with the construct.

For inducible expression of human NAChR subunit-encoding DNA in a mammalian cell, the DNA can be inserted into a plasmid such as pMSG. This plasmid contains the mouse mammary tumor virus (MMTV) promoter for steroid-inducible expression of operatively associated foreign DNA. If the host cell does not express endogenous glucocorticoid receptors required for uptake of glucocorticoids (i.e., inducers of the MMTV promoter) into the cell, it is necessary to additionally transfect the cell with DNA encoding the glucocorticoid receptor (ATCC accession no.

67200). Full-length human DNA clones encoding human a3, 4 a7, ss2 and ss4 have also been subcloned into pIBI24 (International Biotechnologies, Inc., New Haven, CT) or pCMV-T7-2 for synthesis of in vitro transcripts.

In accordance with another embodiment of the present invention, there are provided cells containing the above-described polynucleic acids (i.e., DNA or mRNA). Such host cells as bacterial, yeast, amphibian and mammalian cells can be used for replicating DNA and producing nAChR subunit(s). Methods for constructing expression vectors, preparing in vitro transcripts, transfecting DNA into mammalian cells, injecting oocytes, and performing electrophysiological and other analyses for assessing receptor expression and function as described herein are also described in PCT Application Nos. PCT/US91/02311 (now published as WO 91/15602), PCT/US91/05625 (now published as WO 92/02639) and PCT/US92/11090 (now published as WO 93/13423), and in co-pending U.S. Application Serial Nos. 07/504,455, 07/563,751 and 07/812,254.The subject matter of each of these applications is hereby incorporated by reference herein in its entirety.

Incorporation of cloned DNA into a suitable expression vector, transfection of eukaryotic cells with a plasmid vector or a combination of plasznid vectors, each encoding one or more distinct genes or with linear DNA, and selection of transfected cells are well known in the art (see, e.g., Sambrook et al. (1989) Molecular Cloninq: A Laboratorv Manual, Second Edition, Cold Spring Harbor Laboratory Press). Heterologous DNA may be introduced into host cells by any method known to those of skill in the art, such as transfection with a vector encoding the heterologous DNA by CaPO, precipitation (see, e.g., Wigler et al. (1979) Proc. Natl. Acad. Sci.

76:1373-1376) or lipofectamine (GIBCO BRL #18324-012).

Recombinant cells can then be cultured under conditions whereby the subunit(s) encoded by the DNA is (are) expressed. Preferred cells include mammalian cells (e.g., HEX 293, CHO, GH3 and Ltk cells), yeast cells (e.g., methylotrophic yeast cells, such as Pichia pastoris), bacterial cells (e.g., Escherichia colt), and the like. Especially preferred cells are those which are also capable of expressing endogenous or heterologous voltage-dependent calcium channels (see, for example, PCT Application No. US92/06903; now published as WO 93/C4083).

While the nucleic acids provided herein may be expressed in any eukaryotic cell, including yeast cells (such as, for example, P. pastoris (see U.S. Patent Nos.

4,882,279, 4,837,148, 4,929,555 and 4,855,231), Saccharomyces cerevisie, Candida tropical is, Ransenula polymorpha, and the like), mammalian expression systems, including commercially available systems and other such systems known to those of skill in the art, for expression of nucleic acids encoding the human neuronal nicotinic AChR subunits provided herein are presently preferred. Xenopus oocytes are preferred for expression of RNA transcripts of the DNA.

In preferred embodiments, DNA is ligated into a vector, and introduced into suitable host cells to produce transformed cell lines that express a specific human nNAChR receptor subunit, or specific combinations of subunits. The resulting cell lines can then be produced in quantity for reproducible quantitative analysis of the effects of drugs on receptor function.

In other embodiments, mRNA may be produced by in vitro transcription of DNA encoding each subunit. This mRNA, either from a single subunit clone or from a combination of clones, can then be injected into Xenopus oocytes where the mRNA directs the synthesis of the human receptor subunits, which then form functional receptors.

Alternatively, the subunit-encoding nucleic acids can be directly injected into oocytes for expression of functional receptors. The transfected mammalian cells or injected oocytes may then be used in the methods of drug screening provided herein.

Cloned full-length DNA encoding any of the subunits of human neuronal nicotinic AChR may be introduced into a plasmid vector for expression in a eukaryotic cell. Such DNA may be genomic DNA or cDNA.

Host cells may be transfected with one or a combination of plasmids, each of which encodes at least one human neuronal nicotinic AChR subunit.

Eukaryotic cells in which DNA or RNA may be introduced include any cells that are transfectable by such DNA or RNA or into which such DNA or RNA may be injected. Preferred cells are those that can be transiently or stably transfted and also express the DNA and RNA. Presently most preferred cells are those that can form recombinant or heterologous human neuronal nicotinic AChRs comprising one or more subunits encoded by the heterologous DNA. Such cells may be identified empirically or selected from among those known to be readily transfected or injected.

Exemplary cells for introducing DNA include cells of mammalian origin (e.g., COS cells, mouse L cells, Chinese hamster ovary (CHO) cells, human embryonic kidney cells, African green monkey cells, GH3 cells and other such cells known to those of skill in the art), amphibian cells (e.g., Xenopus laevis obcytes), yeast cells (e.g., Saccharomyces cerevisiae, Pichia pastoris), and the like.Exemplary cells for expressing injected RNA transcripts include Xenopus laevis obcytes. Cells that are preferred for transfection of DNA are known to those of skill in the art or may be empirically identified, and include HEK 293 (which are available from ATCC under accession #CURL 1573); Ltk cells (which are available from ATCC under accession SCCL1.3); COS-7 cells (which are available from ATCC under accession #CURL 1651); GH3 rat pituitary tumor cells (ATCC Accession No.

CCL 82.1) and DG44 cells (dhfr CHO cells; see, e.g., Urlaub et al. (1986) Cell. Molec. Genet. 12: 555).

Presently preferred cells include DG44 cells, GH3 and HEK 293 cells, particularly HEK 293 cells that have been adapted for growth in suspension and that can be frozen in liquid nitrogen and then thawed and regrown. HEK 293 cells are described, for example, in U.S. Patent No.

5,024,939 to Gorman (see, also, Stillman et al. (1985) Mol. Cell. Biol. 5:2051-2060). Presently preferred cells also include those which are capable of expressing endogenous or heterologous voltage-dependent calcium channels.

Nucleic acids may be stably incorporated into cells or may be transiently introduced using methods known in the art. Stably transfected mammalian cells may be prepared by transfecting cells with an expression vector having a selectable marker gene (such as, for example, the gene for thymidine kinase, dihydrofolate reductase, neomycin resistance, and the like), and growing the transfected cells under conditions selective for cells expressing the marker gene. To produce such cells, the cells should be transfected with a sufficient concentration of subunit-encoding nucleic acids to form human neuronal nicotinic AChRs that contain the human subunits encoded by heterologous DNA. The precise amounts and ratios of DNA encoding the subunits may be empirically determined and optimized for a particular combination of subunits1 cells and assay conditions.

Recombinant cells that express neuronal nicotinic AChR containing subunits encoded only by the heterologous DNA or RNA are especially preferred.

Heterologous DNA may be maintained in the cell as an episomal element or may be integrated into chromosomal DNA of the cell. The resulting recombinant cells may then be cultured or subcultured (or passaged, in the case of mammalian cells) from such a culture or a subculture thereof. Methods for transfection, injection and culturing recombinant cells are known to the skilled artisan. Similarly, the human neuronal nicotinic AChR subunits may be purified using protein purification methods known to those of skill in the art. For example, antibodies or other ligands that specifically bind to one or more of the subunits may be used for affinity purification of the subunit or human neuronal nicotinic AChRs containing the subunits.

In accordance with yet another embodiment of the present invention, there are provided antibodies generated against the ss4 subunit proteins of the invention.

Such antibodies can be employed for studying receptor tissue localization, subunit composition, structure of functional domains, as well as in diagnostic applications, therapeutic applications, and the like.

Preferably, for therapeutic applications, the antibodies employed will be monoclonal antibodies.

The above-described antibodies can be prepared employing standard techniques, as are well known to those of skill in the art, using the invention subunit proteins or portions thereof as antigens for antibody production.

Both anti-peptide and anti-fusion protein antibodies can be used (see, for example1 Bahouth et al. (1991) Trends Pharmacol Sci. vol. 12:338-343; Current Protocols in Molecular Biology (Ausubel et al., eds.) John Wiley and Sons, New York (1989)]. Factors to consider in selecting portions of the NAChR beta subunits for use as imunogen (as either a synthetic peptide or a recombinantly produced bacterial fusion protein) include antigenicity, accessibility (i.e., extracellular and cytoplasmic domains), uniqueness to the particular subunit, etc.

The availability of subunit-specific antibodies makes possible the application of the technique of immunohistochemistry to monitor the distribution and expression density of various subunits (e.g., in normal vs diseased brain tissue). Such antibodies could also be employed for diagnostic and therapeutic applications.

In accordance with still another embodiment of the present invention, there are provided methods for modulating the ion channel activity of receptor(s) of the invention by contacting said receptor(s) with an effective amount of the above-described antibodies.

The antibodies of the invention can be administered to a subject employing standard methods, such as, for example, by intraperitoneal, intramuscular, intravenous, or subcutaneous injection, implant or transdermal modes of administration, and the like. One of skill in the art can readily determine dose forms, treatment regiments, etc, depending on the mode of administration employed.

In accordance with one embodiment of the present invention, methods for producing cells that express human neuronal nicotinic AChw ss, subunits and functional receptors are also provided. In one such method, host cells are transfected with DNA encoding at least one alpha subunit of a neuronal nicotinic acetylcholine receptor and at least the ss4 subunit of a neuronal nicotinic acetylcholine receptor. Using methods such as northern blot or slot blot analysis, transfected cells that contain alpha and/or beta subunit encoding DNA or RNA can be selected. Transfected cells are also analyzed to identify those that express NAChR protein.

Analysis can be carried out, for example, by measuring the ability of cells to bind acetylcholine, nicotine, or a nicotine agonist, compared to the nicotine binding ability of untransfected host cells or other suitable control cells, by electrophysiologically monitoring the currents through the cell membrane in response to a nicotine agonist, and the like.

In particularly preferred aspects, eukaryotic cells which contain heterologous DNAs express such DNA and form recombinant functional neuronal nicotinic AChR(s). In more preferred aspects, recombinant neuronal nicotinic AChR activity is readily detectable because it is a type that is absent from the untransfected host cell or is of a magnitude not exhibited in the untransfected cell. Such cells that contain recombinant receptors could be prepared, for example, by causing cells transformed with DNA encoding the human neuronal nicotinic AChR 3 and ss4 subunits to express the corresponding proteins. The resulting synthetic or recombinant receptors would contain only the 3 and ss nNAChR subunits.Such receptors would be useful for a variety of applications, e.g., as part of an assay system free of the interferences frequently present in prior art assay systems employing non-human receptors or human tissue preparations. Furthermore, testing of single receptor subunits with a variety of potential agonists or antagonists would provide additional information with respect to the function and activity of the individual subunits. Such information is expected to lead to the identification of compounds which are capable of very specific interaction with one or more of the receptor subunits. Such specificity may prove of great value in medical application.

In another aspect, the invention comprises functional peptide fragments, and functional combinations thereof, encoded by the DNAs of the invention. Such functional peptide fragments can be produced by those skilled in the art, without undue experimentation, by eliminating some or all of the amino acids in the sequence not essential for the peptide to function as a NAChR. A determination of the amino acids that are essential for NAChR function is made, for example, by systematic digestion of the DNAs encoding the peptides and/or by the introduction of deletions into the DNAs.

The modified (e.g., deleted or digested) DNAs ae expressed, for example, by transcribing the DNA and then introducing the resulting mRNA into Xenopus oocytes, where translation of the mRNAs will occur. Functional analysis of the proteins thus expressed in the oocytes is accomplished by exposing the oocytes to ligands known to bind to and functionally activate NAChR, and then monitoring the oocytes to see if endogenous channels are in turn activated. If currents are detected, the fragments are functional as NAChR.

Thus. DNA encoding human neuronal nicotinic AchR ss4 subunit may be introduced into suitable host cells (e.g., eukaryotic or prokaryotic cells) for expression of the subunit and functional NAChRs.

Preferably combinations of alpha and beta subunits may be introduced into cells: such combinations include combinations of any one or more of a a2, a3, a4, a5 and at with ss4. Sequence information for a1 is presented in Biochem. Soc. Trans. (1989) 17:219-220; sequence information for aS is presented in Proc. Natl. Acad.

Sci.USA (1992) 89:1572-1576; and sequence information for a2, a3, a4, , α7, ss2 and ss4 is presented in the Sequence Listing provided herewith. Presently preferred combinations of subunits include any one or more of a1, a2, a3 or a4 with ss4; or a2, a3 or a4 in combination with It It is recognized that some of the subunits may have ion transport function in the absence of additional subunits. For example, the α7 subunit may function in the absence of any added beta subunit.

As used herein, "a2 subunit DNA" refers to DNA that encodes a human neuronal nicotinic acetylcholine receptor subunit of the same name, and to DNA that hybridizes under conditions of high stringency to the DNA of SEQ ID No. 1, or to the DNA of deposited clone having ATCC Accession No. 68277, or to DNA that encodes the amino acid sequence set forth in SEQ ID No. 2.

Typically, unless an a2 subunit arises as a splice variant, an a2 DNA shares substantial sequence homology (greater than about 90%) with the a2 DNA described herein.

DNA or RNA encoding a splice variant may share less than 90% overall sequence homology with the DNA or RNA described herein, but such a splice variant would include regions of nearly 100% homology to the above-described: DNA.

As used herein, "a3 subunit DNA" refers to DNA that encodes a neuronal subunit of the same name, and to DNA that hybridizes under conditions of high stringency to the DNA of SEQ ID No. 3, or to the DNA of deposited clone having ATCC Accession No. 68278, or to DNA that encodes the amino acid sequence set forth in SEQ ID No.

4. Typically, unless an a3 arises as a splice variant, an a3 DNA shares substantial sequence homology (greater than about 90%) with the α3 DNA described herein. DNA or RNA encoding a splice variant may share less than 90% overall sequence homology with the DNA or RNA provided herein, but such a splice variant would include regions of nearly 100% homology to the above described DNA.

As used herein, "aS subunit DNA" refers to DNA that encodes a human neuronal nicotinic acetylcholine receptor subunit of the same name, as described, for example, by Chini et al. (1992) Proc. Natl. Acad. Sci.

USA 89:1572-1576.

As used herein, "fl2 subunit DNA" refers to DNA that encodes a neuronal subunit of the same name and, to DNA that hybridizes under conditions of high stringency to the DNA of SEQ ID No. 9, or to the DNA of deposited clone HnACh2, having ATCC Accession No. 68279, or to DNA encoding the amino acid sequence set forth in SEQ ID No. 10. Typically, unless a ss2 subunit arises as a splice variant, a 2 DNA shares substantial sequence homology (9reater than about 90%) with the ss2 DNA described heiein.

DNA or RNA encoding a splice variant may share overall less than 90% homology with the DNA or RNA provided herein, but such a splice variant would include regions of nearly 100% homology to the above-described DNA.

In certain embodiments, eukaryotic cells with heterologous human neuronal nicotinic AChRs are produced by introducing into the cell a first composition, which contains at least one RNA transcript that is translated in the cell into a subunit of a human neuronal nicotinic AChR in accordance with the invention. In preferred embodiments, the subunits that are translated also include an alpha subunit of a human neuronal nicotinic AChR. More preferably, the composition that is introduced contains an RNA transcript which encodes an alpha subunit and also contains an RNA transcript which encodes a beta subunit of a human neuronal nicotinic AChR. RNA transcripts can be obtained from cells transfected with DNAs encoding human neuronal nicotinic acetylcholine receptor subunits or by in vitro transcription of subunit-encoding DNAs.Methods for in vitro transcription of cloned DNA and injection of the resulting mRNA into eukaryotic cells are well known in the art. Amphibian oocytes are particularly preferred for expression of in vitro transcripts of the human nNAChR DNA clones provided herein. See, for example, Dascal (1989) CRC Crit. Rev. Biochem. 22:317-387, for a review of the use of Xenopus oocytes to study ion channels.

Thus, pairwise (or stepwise) introduction of DNA or RNA encoding alpha and beta subunits into cells is possible. The resulting cells may be tested by the methods provided herein or known to those of skill in the art to detect functional AChR activity. Such testing will allow the identification of pairs of alpha and beta subunits that produce functional AChRs, as well as individual subunits that produce functional AChRs.

As used herein, a recombinant or heterologous human neuronal nicotinic AChR refers to a receptor that contains one or more subunits encoded by heterologous DNA that has been introduced into and expressed in cells capable of expressing receptor protein. A recombinant human neuronal nicotinic AChR may also include subunits that are produced by DNA endogenous to the host cell. In certain embodiments, recombinant or heterologous human neuronal nicotinic AChR may contain only subunits that are encoded by heterologous DNA.

Recombinant receptors on recombinant eukaryotic cell surfaces may contain one or more subunits encoded by the DNA or mRNA encoding human neuronal nicotinic AChR subunits, or may contain a mixture of subunits encoded by the host cell and subunits encoded by heterologous DNA or mRNA. Recombinant receptors may be homogeneous or may be a mixture of subtypes. Mixtures of DNA or mRNA encoding receptors from various species, such as rats and humans, may also be introduced into the cells. Thus, a cell can be prepared that expresses recombinant receptors containing only a3 and ss4 subunits, or any other combination of alpha and ss4 subunits provided herein.

For example, α4 and/or 7 subunits of the present invention can be co-expressed ss4 receptor subunits; similarly, ss4 subunits according to the present invention can be co-expressed with a2, a3, a4, a5 and/or a7 receptor subunits. As noted previously, some of the nNAChR subunits may be capable of forming functional receptors in the absence of other subunits, thus coexpression is not always required to produce functional receptors.

As used herein, activity of a human neuronal nicotinic AChR refers to any activity characteristic of an NAChR. Such activity can typically be measured by one or more in vitro methods, and frequently coliesponds to an in vivo activity of a human neuronal nicotinic AChR.

Such activity may be measured by any method known to those of skill in the art, such as, for example, measuring the amount of current which flows through the recombinant channel in response to a stimulus.

Methods to determine the presence and/or activity of human neuronal nicotinic AChRs include assays that measure nicotine binding, MRb ion-flux, Ca influx, the electrophysiological response of cells, the electrophysiological response of oocytes transfected with RNA from the cells, and the like. In particular, methods are provided herein for the measurement or detection of an AChR-mediated response upon contact of cells containing the DNA or mRNA with a test compound.

As used herein, a functional neuronal nicotinic AChR is a receptor that exhibits an activity of neuronal nicotinic AChRs as assessed by any in vitro or in vivo assay disclosed herein or known to those of skill in the art. Possession of any such activity that may be assessed by any method known to those of skill in the art and provided herein is sufficient to designate a receptor as functional. Methods for detecting NAChR protein and/or activity include, for example, assays that measure nicotine binding, MRb ion-flux, Ca2 influx, the electrophysiological response of cells containing heterologous DNA or mRNA encoding one or more receptor subunits, and the like. Since all combinations of alpha and beta subunits may not form functional receptors, numerous combinations of alpha and beta subunits, in particular ss4 subunits should be tested in order to fully characterize a particular subunit and cells which produce same. Thus, as used herein, "functional" with respect to a recombinant or heterologous human neuronal nicotinic AChR means that the receptor channel is able to provide for and regulate entry of human neuronal nicotinic AChR-permeable ions, such as, for example, Na, K', Ca2 or Bay1, in response to a stimulus and/or bind ligands with affinity for the receptor.Preferably such human neuronal nicotinic AChR activity is distinguishable, such as by electrophysiological, pharmacological and other means known to those of skill in the art, from any endogenous nicotinic AChR activity that may be produced by the host cell.

In accordance with a particular embodiment of the present invention, recombinant human neuronal nicotinic AChR-expressing mammalian cells or oocytes can be contacted with a test compound, and the modulating effect(s) thereof can then be evaluated by comparing the AChR-mediated response in the presence and absence of test compound, or by comparing the AChR-mediated response of test cells, or control cells (i.e., cells that do not express nNAChRs), to the presence of the compound.

As used herein, a compound or signal that "modulates the activity of a neuronal nicotinic AChR1, refers to a compound or signal that alters the activity of NAChR so that activity of the NAChR is different in the presence of the compound or signal than in the absence of the compound or signal. In particular, such compounds or signals include agonists and antagonists.

The term agonist refers to a substance or signal, such as ACh, that activates receptor function; and the term antagonist refers to a substance that interferes with receptor function. Typically, the effect of an antagonist is observed as a blocking of activation by an agonist. Antagonists include competitive and noncompetitive antagonists. A competitive antagonist (or competitive blocker) interacts with or near the site specific for the agonist (e.g., ligand or neurotransmitter) for the same or closely situated site.

A non-competitive antagonist or blocker inactivates the functioning of the receptor by interacting with a site other than the site that interacts with the agonist.

As understood by those of skill in the art, assay methods for identifying compounds that modulate human neuronal nicotinic AChR activity (e.g., agonists and antagonists) generally require comparison to a control. One type of a "control" cell or "control" culture is a cell or culture that is treated substantially the same as the cell or culture exposed to the test compound, except the control culture is not exposed to test compound. For example, in methods that use voltage clamp electrophysiological procedures, the same cell can be tested in the presence and absence of test compound, by merely changing the external solution bathing the cell. Another type of "control" cell or "control" culture may be a cell or a culture of cells which are identical to the transfected cells, except the cells employed for the control culture do not express functional human neuronal nicotinic AChRs.In this situation, the response of test cell to test compound is compared to the response (or lack of response) of receptor-negative (control) cell to test compound, when cells or cultures of each type of cell are exposed to substantially the same reaction conditions in the presence of compound being assayed.

The functional recombinant human neuronal nicotinic AChR can include at least an alpha subunit, but in accordance with the invention includes an alpha subunit and a ss4 subunit of a human neuronal nicotinic AChR. Eukaryotic cells expressing these subunits have been prepared by injection of RNA transcripts and by transfection of DNA. Such cells have exhibited nicotinic AChR activity attributable to human neuronal nicotinic AChRs that contain one or more of the heterologous human neuronal nicotinic AChR subunits.For example, Xenopus laevis oocytes that had been injected with in vitro transcripts of the DNA encoding human neuronal nicotinic AChR a3 and t subunits exhibited AChR agonist induced currents; whereas cells that had been injected with transcripts of either the a3 or ss subunit alone did not. In addition, HEK 293 cells that had been co-transfected with DNA encoding human neuronal NAChR ass and ss subunits exhibited AChR agonist-induced increases in intracellular calcium concentration, whereas control HEX 293 cells (i.e., cells that had not been transfected with a3- and ss4-encoding DNA) did not exhibit any AChR agonist-induced increases in intracellular calcium concentration.

With respect to measurement of the activity of functional heterologous human neuronal nicotinic AChRs, endogenous AChR activity and, if desired, activity of AChRs that contain a mixture of endogenous host cell subunits and heterologous subunits, should, if possible, be inhibited to a significant extent by chemical, pharmacological and electrophysiological means.

Deposits The deposited clones have been deposited at the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, U.S.A. 20852, under the terms of the Budapest Treaty on the International Recognition of Deposits of Microorganisms for Purposes of Patent Procedure and the Regulations promulgated under this Treaty. Samples of the deposited material are and will be available to industrial property offices and other persons legally entitled to receive them under the terms of the Treaty and Regulations and otherwise in compliance with the patent laws and regulations of the United States of America and all other nations or international organizations in which this application, or an application claiming priority of this application, is filed or in which any patent granted on any such application is granted.In particular, upon issuance of a U.S. patent based on this or any application claiming priority to or incorporating this application by reference thereto, all restrictions upon availability of the deposited material will be irrevocably removed.

The invention will now be described in greater detail with reference to the following non-limiting examples.

Example 1 Isolation of DNA Encoding Human nNAChR Subunits A. DNA Encoding a Human nNAChR Bz Subunit Random primers were used in synthesizing cDNA from RNA isolated from the IMR32 human neuroblastoma cell line (the cells had been grown in lmM dibutyryl cAMP for 10 days prior to constructing the library). The library constructed from the cDNAs was screened with a fragment of a rat nicotinic AChR ss4 subunit cDNA. Hybridization was performed at 420C in 5X SSPE, 5X Denhardt's solution, 50% formamide, 200 pglml herring sperm DNA and 0.2% SDS.

Washes were performed in 0.1X SSPE, 0.2S SDS at 650C.

Five clones were identified that hybridized to the probe.

The five clones were plaque-purified and characterized by restriction enzyme mapping and DNA sequence analysis. The insert DNA of one of the five clones contained the complete coding sequence of a subunit of a human nicotinic AChR (see nucleotides 871583 of SEQ ID No. 11). The amino acid sequence deduced from the nucleotide sequence of the full-length clone has -82% identity with the amino acid sequence deduced from the rat nicotinic AChR fi4 subunit DNA. Several regions of the deduced rat and human t amino acid sequences are notably dissimilar: amino acids 1-23 (the human sequence has only -36% identity with respect to the rat sequence), 352-416 (the human sequence has only -48% identity with respect to the rat sequence), and 417-492 (the human sequence has only -78% identity with respect to the rat sequence).Furthermore, amino acids 376-379 in the rat subunit are not contained in the human t subunit.

B. DNA Encoding a Human nNAChR a7 Subunit An amplified IMR32 cell cDNA library (1 x 106 recombinants; cells treated for 10 days with lmM dibutyryl cAMP prior to library construction) was screened with a fragment of a rat nicotinic AChR a7 subunit cDNA. The hybridization conditions were identical to those described above for screening an IMR32 cell cDNA library with the rat ss subunit DNA. Washes were performed in 0.2X SSPE, 0.2% SDS at 650C. Seven positive clones were identified by hybridization to the labeled rat DNA probe. Six of the clones were plaquepurified and characterized by restriction enzyme mapping and DNA sequence analysis. One of the clones contains the complete coding sequence of a human AChR receptor a7 subunit gene (see nucleotides 73-1581 of SEQ ID No. 7).

C. DNA Encoding a Human nNAChR a, Subunit Random primers were used in synthesizing cDNA from RNA isolated from human hippocampus tissue. cDNAs larger than 2.0 kb were inserted into the AgtlO phage vector to create a cDNA library. Approximately 1 x 106 recombinants were screened with a fragment of a DNA encoding a rat nicotinic AChR a4 subunit using the same hybridization and washing conditions as described above for screening an 1my32 cell cDNA library for 7 subunit cDNAs. Three clones hybridized strongly to the probe.

Two of these three clones, designated KEa4.1 and KEa4.2, have been deposited with the American Type Culture Collection (ATCC, Rockville, MD) and assigned accession nos. 69152 and 69239, respectively.

Characterization of the plaque-purified clones revealed that one of the clones, KEa4.2, contains the complete coding sequence of a human nicotinic AChR a4 subunit gene (coding sequence of this human α4 subunit cDNA is provided as nucleotides 173-2056 in SEQ ID No.

5). Comparison of the 5' ends of the coding sequences of the human and rat a4 subunit cDNAs reveals, among other differences, that the rat sequence contains an 18nucleotide segment that is not present in the human sequence.

D. DNA Encoding Human nNAChR α2, α3, & ss2 Subunits Plasmids containing DNA that encodes and/or that can be used to isolate nucleic acids that encode human neuronal nicotinic acetylcholine receptor α2, a3 and ss2 subunits have been deposited with the American Type Culture Collection (ATCC). The clone names and deposit accession numbers are: Subunit Clone Name ATCC Accession No.

a2 HnAChRa2 68277 as HnACHRa3 68278 ss2 HnAChRss2 68279 In addition, DNA sequences that encode fulllength a2, as and 2 subunits are set forth in SEQ ID Nos.

1, 3 and 9, respectively.

Example 2 Preparation of Constructs for the Expression of Recombinant Human Neuronal Nicotinic AChR Subunits Isolated cDNAs encoding human neuronal nicotinic AChR subunits were incorporated into vectors for use in expressing the subunits in mammalian host cells and for use in generating in vitro transcripts to be expressed in Xenopus oocytes. Several different vectors were utilized in preparing the constructs as follows.

A. Construct for Expression of a Human nNAChR a3 Subunit DNA encoding a human neuronal nicotinic AChR a3 subunit was subcloned into the pCMV-T7-2 general expression vector to create pCMV-KEa3. Plasmid pCMV-T7-2 (see Figure 1) is a pUCl9-based vector that contains a CMV promoter/enhancer, SV40 splice donor/splice acceptor sites located immediately downstream of the promoter, a T7 bacteriophage RNA polymerase promoter positioned downstream of the SV40 splice sites, an SV40 polyadenylation signal downstream of the T7 promoter, and a polylinker between the T7 promoter and the polyadenylation signal. This vector thus contains all the regulatory elements required for expression of heterologous DNA in a mammalian host cell, wherein the heterologous DNA has been incorporated into the vector at the polylinker.In addition, because the T7 promoter is located just upstream of the polylinker, this plasmid can be used for synthesis of in vitro transcripts from heterologous DNA that has been subcloned into the vector at the polylinker. Figure 1 also shows a restriction map of pCMV-T7-3. This plasmid is identical to pCMV-T7-2 except that the restriction sites in the polylinker are in the opposite order as compared tothe order in which they occur in pCMV-T7-2.

A 1.7 kb SfiI (blunt-ended)/EcoRI DNA fragment containing nucleotides 27-1757 of SEQ ID No. 3 (i.e., the entire a3 subunit coding sequence plus 12 nucleotides of 5' untranslated sequence and 204 nucleotides of 3' untranslated sequence) was ligated to EcoRV/EcoRIdigested pCMV-T7-2 to generate pCMV-KEa3. Plasmid pCMV-KEa3 was used for expression of the a3 subunit in mammalian cells and for generating in vitro transcripts from the a3 subunit DNA.

B. Constructs for Expression of a Human nNAChR BX Subunit A 1.9 kb EcoRI DNA fragment containing nucleotides 1-1915 of SEQ ID No. 11 (i.e., the entire B1 subunit coding sequence plus 86 nucleotides of 5' untranslated sequence and 332 nucleotides of 3' untranslated sequence) was ligated to EcoRI-digested pGEM7Zf(+) (Promega Catalog SP2251; Madison, WI). The resulting construct, KEB4.6/pGEM, contains the T7 bacteriophage RNA polymerase promoter in operative association with two tandem ss4 subunit DNA inserts (in the same orientation) and was used in generating in vitro transcripts from the DNA.

The same 1.9 kb EcoRI DNA fragment containing nucleotides 1-1915 of SEQ ID No. 11 was ligated as a single insert to EcoRI-digested pCMV-T7-3 to generate pCMV-KEB4. Plasmid pCMV-KEss4 was used for expression of the 4 subunit in mammalian cells and for generating in vitro transcripts of the t subunit DNA.

C. ConstrCts for Expression of a Human nNAChR a7 Subunit Two pCMV-T7-based constructs were prepared for use in recombinant expression of a human neuronal nicotinic AChR a7 subunit. The first construct, pCMV-KEa7.3, was prepared by ligating a 1.9 kb XhoI DNA fragment containing nucleotides 1-1876 of SEQ ID No. 7 (i.e., the entire 7 subunit coding sequence plus 72 nucleotides of 5' untranslated sequence and 295 nucleotides of 3' untranslated sequence) to Sail-digested pCMV-T7-3. The second construct, pCMV-KEa7, was prepared by replacing the 5' untranslated sequence of the 1.9 kb Xhol α7 subunit DNA fragment described above with a consensus ribosome binding site (5'-GCCACC-3'; see Kozak (1987) Nucl.Acids Res. 15:8125-8148). The resulting modified fragment was ligated as a 1.8 kb ssglII/XhoI fragment with BglIIlSalI-digested pCMV-T7-2 to generate pCMV-XEa7. Thus, in pCMV-XEa7, the translation initiation codon of the coding sequence of the a7 subunit cDNA is preceded immediately by a consensus ribosome binding site.

D. Constructs for ExPression of a Human nNAChR B2 Subunit DNA fragments encoding portions of a human neuronal nicotinic AChR 2 subunit were ligated together to generate a full-length ss2 subunit coding sequence contained in plasmid pIB124 (International Biotechnologies, Inc. (IBI), New Haven, CT). The resulting construct, Hss2.1F, contains nucleotides 1-2448 of SEQ ID No. 9 (i.e., the entire 2 subunit coding sequence, plus 264 nucleotides of 5' untranslated sequence and 675 nucleotides of 3' untranslated sequence) in operative association with the T7 promoter.

Because the 5' untranslated sequence of the'by subunit DNA contains a potential alternative translation initiation codon (ATG) beginning 11 nucleotides upstream (nucleotides 254-256 in SEQ ID No. 9) of the correct translation initiation codon (nucleotides 265-267 in SEQ ID No. 9), and because the use of the upstream ATG sequence to initiate translation of the ss2 DNA might result in the generation of an inoperative peptide (because the upstream ATG is not in the correct reading frame), an additional ss2-encoding construct was prepared as follows.A 2.2 kb KspI (blunt ended)/EcoRI DNA fragment containing nucleotides 260-2448 of SEQ ID No. 9 was ligated to NotI (blunt ended)/EcoRI-digested pCMV-T7-3 in operative association with the T7 promoter of the plasmid to create pCMV-KEB2. The P2 subunit DNA contained in pCMV-KEss2 retains only 5 nucleotides of 5' untranslated sequence upstream of the correct translation initiation codon.

DNA encoding a human NAChR ss2 subunit was also incorporated into expression vector pSP64T. Vector pSP64T (see Krieg and Melton in Nucleic Acids Research 12:7057-7070 (1984)] is a modified form of vector pSP64 (Promega). The human NAChR ss2 subunit coding sequence (preceded by the consensus ribosome binding site), plus 405 nucleotides of 3' untranslated region, were incorporated into pSP64T at a unique restriction enzyme cloning site that is flanked by 5' and 3' untranslated sequences from the Xenopus ss-globin gene. These sequences are located downstream of the SP6 promoter contained in pSP64T.The resulting vector, pSP64T-KEss2RBSl, contains the human ss2 subunit coding sequence in operable association with SP6 transcription regulatory regions for the production of in vitro transcripts of the heterologous DNA using the MEGAscript SP6 kit (Ambion, Catalog No. 1330).

E. Constructs for ExPression of a Human nNAChR a, Subunit A portion of the insert of clone KEa4.2 (see Example 1C), containing a human nNAChR a4 subunit coding sequence, was incorporated into a modified vector pIBI24 as follows. Vector pIBI24 was modified by inserting a consensus ribosome binding site into the polylinker just upstream of an NotI site. The vector was digested with HindlII and NcoI.An Ncol-HindIII fragment containing a human nNAChR an subunit coding sequence was obtained by digestion of a human nNAChR 4 subunit cDNA-containing plasmid with HindlII (which cuts in a polylinker immediately 3' to the 3'untranslated sequence of KEα4.2 (see SEQ ID NO:5), followed by partial digestion with NcoI (to maintain an internal Ncol site, i.e., position 1956, SEQ ID NO:5) to cut at the junction of the translation initiation codon and 5 untranslated sequence of the a4 subunit-encoding cDNA. The resulting 3.25 kb fragment was ligated with the HindIII-NcoI fragment of the modified pIBI24 vector to create pIBI-KEa4RBSf.

Thus, pIBI-KEa4RBSf contains a consensus ribosome binding site followed immediately by the human nNAChR a4 subunit coding sequence (nucleotides 173-2056 of SEQ ID NO:5) and 1400 nucleotides of 3' untranslated sequence (including nucleotides 2057 - 2363 of SEQ ID NO:5). Because this construct contains a T7 promoter upstream of the an subunit coding sequence, it can be used in generating in vitro transcripts from a4 DNA.

Example 3 Expression of Recombinant Human Nicotinic AChR in Oocvtes Xenopus oocytes were injected with in vitro transcripts prepared from constructs containing DNA encoding a3, 7 ss2 and B subunits. Electrophysiological measurements of the oocyte transmembrane currents were made using the two-electrode voltage clamp technique (see, e.g., Stuhmer (1992) Meth. Enzymol. 207:319-339).

1. Preparation of in vitro transcripts Recombinant capped transcripts of pCMV-KEa3, pCMV-KEss2, KEB4.6/pGEM and pCMV-KEB4 were synthesized from linearized plasmids using the mCAP RNA Capping Kit (Cat. #200350 from Stratagene, Inc., La Jolla, CA).

Recombinant capped transcripts of pCMV-KEa7, pCMV-KEa7.3, pIBI-KEa4RBSf and HB2.lF were synthesized from linearized plasmids using the MEGAscript T7 in vitro transcription kit according to the capped transcript protocol provided by the manufacturer (Catalog 21334 from AMBION, Inc., Austin, TX). The mass of each synthesized transcript was determined by UV absorbance and the integrity of each transcript was determined by electrophoresis through an agarose gel.

2. Electrophysioloqy Xenopus oocytes were injected with either 12.5, 50 or 125 ng of human nicotinic AChR subunit transcript per oocyte. The preparation and injection of oocytes were carried out as described by Dascal (1987) in Crit.

Rev. Biochem. 22:317-387. Two-to-six days following mRNA injection, the oocytes were examined using the twoelectrode voltage clamp technique. The cells were bathed in Ringer's solution (115 mM NaCl, 2.5 mM KC1, 1.8 mM CaCl2, 10 mM HEPES, pH 7.3) containing 1 M atropine with or without 100 tAM d-tubocurarine.'.' Cells were voltageclamped at -60 to -80 mV. Data were acquired with Axotape software at 2-5 Hz. The agonists acetylcholine (ACh), nicotine, and cytisine were added at concentrations ranging from 0.1 tAM to 100 M. The results of electrophysiological analyses of the oocytes are summarized in Table 1.

Table 1

Template, ng RNA Number of Agonists Current injected oocytes Amplitude responding pCMV-KE&alpha;3, 12.5 ng 0 of 8 Ach, Nicotine KEss4.6/pGEM, 12.5 ng 0 of 9 ACh, Nicotine pCMV-KE&alpha;3, 12.5 ng 4 of 5 ACh, 20-550 nA + Nicotine KEss4.6/pGEM, 12.5 ng pCMV-KE&alpha;;3, 12.5 ng 3 of 4 ACh, 20-300 nA + Cytisine, KEss4.6/pGEM, 12.5 ng Nicotine pCMV-KE&alpha;3, 125 ng 5 of 5 ACh, 200-500 + Nicotine, nA and pCMV-KEss4, 125 ng Cytisine pCMV-KE&alpha;3, 125 ng 6 of 6 ACh, 100-400 + Nicotine, nA pCMV-KEss4, 125 ng Cytisine pCMV-KE&alpha;7.3, 125 ng 3 of 15 ACh -20 nA pCMV-KE&alpha;;7, 125 ng 11 of 11 ACh 20-250 nA pCMV-KE&alpha;3, 12.5 ng 2 of 9 ACh, < 10 nA + Nicotine pCMV-KEss2, 12.5 ng pCMV-KE&alpha;3, 125 ng 0 of 9 ACh, + Nicotine pCMV-KEss2, 125 ng pCMV-KE&alpha;3, 125 ng 13 of 16 ACh (100 M) -20 nA + ACh (300 M) -80 nA Hss2.1F, 125 ng pIBI-KE&alpha;;4RBSf, 125 ng 3 of 3 ACh (30 M) -40 nA + pCMV-KEss4, 125 ng a. Oocytes Injected with &alpha;3, &alpha;4 and/or ss4 Transcripts Oocytes that had been injected with 12.5 ng of the a3 transcript or 12.5 ng of the transcript did not respond to application of up to 100 pM ACh, nicotine or cytisine. Thus, it appears that these subunits do not form functional homomeric nicotinic AChR channels.By contrast, oocytes injected with 12.5 or 125 ng of the a3 transcript and 12.5 ng or 125 ng of the 4 transcript exhibited detectable inward currents in response to ACh, nicotine, and cytisine at the tested concentrations (0.1 pM to 10 pM). Some differences in the kinetics of the responses to cytisine compared to nicotine and ACh were observed. The relative potency of the agonists appeared to be cytisine > ACh > nicotine, which differs from the results of similar studies of oocytes injected with transcripts of the rat nicotinic AChR a3 and ss4 subunits (see, for example, Luetje et al. (1991) J.

Neurosci. 11:837-845) The responses to ACh and nicotine were reproducibly blocked by d-tubocurarine. For example, complete blockage of the response to ACh was observed in the presence of 100 UM d-tubocurarine. The inhibition appeared to be reversible. The responses to ACh, nicotine and cytisine were also at least partially blocked by 100 nM mecamylamine.

The current response of a3-8,-injected oocytes to 10 pM ACh was also examined in terms of membrane voltage. In these experiments, voltage steps were applied to the cells in the presence of ACh. The graph of current vs. voltage appeared typical of responses observed for Na, K -permeable channels. For example, the zero current level (reversal potential) is less than -40 mV. The contribution of Ca flux to the total current can be ascertained by varying the calcium concentration in the external medium and taking multiple current measurements at different holding potentials around the reversal potential.Such studies indicate that the channel carrying the current generated in response to ACh treatment of &alpha;3-ss4-injected oocytes is permeable to Na', K@ and Ca".

As shown in Table 1, oocytes injected with 125 ng of the a4 transcript and 125 ng of the ss transcript also exhibited detectable inward currents in response to acetylcholine.

b. Oocvtes iniected with a7 subunit transcripts As described in Example 2, two constructs were prepared for use in expressing the human neuronal nicotinic AChR a7 subunit. Plasmid pCMV-KEa7.3 contains the &alpha;7 subunit coding sequence with 72 nucleotides of 5' untranslated sequence upstream of the translation initiation codon. Plasmid pCMV-KEa7 contains the a7 subunit coding sequence devoid of any 5' untranslated sequence and further contains a consensus ribosome binding site immediately upstream of the coding sequence.

Oocytes injected with 125 ng of a7 transcript synthesized from pCMV-KEa7 displayed inward currents in response to 10 or 100 pM ACh. This response was blocked by 100 pM d-tubocurarine.

Oocytes injected with 125 ng of a7 transcript synthesized from pCMV-KEa7.3 exhibited ACh-induced currents that were substantially weaker than those of oocytes injected with a7 transcript synthesized from pCMV-KE&alpha;7. These results indicate that human neuronal nicotinic AChR a7 subunit transcripts generated from &alpha;7 subunit DNA containing a ribosome binding site in place of 5' untranslated sequence may be preferable for expression of the 7 receptor in oocytes.

c. Oocvtes injected with &alpha;3 and ss2 subunit transcrints As described in Example 2, two constructs were prepared for use in expressing the human neuronal nicotinic AChR 2 subunit. Plasmid 2.1F contains the by subunit coding sequence with 266 nucleotides of 5' untranslated sequence upstream of the translation initiation codon. Plasmid pCMV-KEss2 contains the subunit coding sequence and only 5 nucleotides of 5' untranslated sequence upstream of the translation initiation codon.

Oocytes injected with transcripts of pCMV-XEa3 and pCMV-KEss2 displayed substantially no current in response to nicotinic AChR agonists. In contrast, oocytes injected with transcripts of pCMV-KEa3 and HB2.1F displayed -20 nA inward currents in response to 100 pM ACh and -80 nA inward currents in response to 300 M ACh.

The current response was blocked by 100 pM d-tubocurarine.

Example 4 Recombinant Expression of Human nNAChR Subunits in Mammalian Cells Human embryonic kidney (HEK) 293 cells were transiently and stably transfected with DNA encoding human neuronal nicotinic AChR a3 and ss4, or a7 subunits.

Transient transfectants were analyzed for expression of nicotinic AChR using various assays, e.g., electrophysiological methods, Ca2-sensitive fluorescent 125 indicator-based assays and [ 2 I)-a-bungarotoxin-binding assays.

1. Transient Transfection of HEK Cells Two transient transfections were performed. In one transfection, HEK cells were transiently cotransfected with DNA encoding a3 (plasmid pCMV-KEa3) and t (plasmid pCMV-KEss4) subunits. In the other transfection, HEK cells were transiently transfected with DNA encoding the &alpha;7 subunit (plasmid pCMV-KE&alpha;7). In both transfections, -2 x 106 HEK cells were transiently transfected with 18 g of the indicated plasmid(s) according to standard CaPO4 transfection procedures [Wigler et al. (1979) Proc. Natl. Acad. Sci. USA 76:13731376].In addition, 2 pg of plasmid pCMVssgal (Clontech Laboratories, Palo Alto, CA), which contains the Escherichia coli -galactosidase gene fused to the CMV promoter, were co-transfected as a reporter gene for monitoring the efficiency of transfection. The transfectants were analyzed for ss-galactosidase expression by measurement of ss-galactosidase activity [Miller (1972) Experiments in Molecular Genetics, pp.352355, Cold Spring Harbor Press). Transfectants can also be analyzed for ss-galactosidase expression by direct staining of the product of a reaction involving ss-galactosidase and the X-gal substrate (Jones (1986) EMBO 5:3133-3142].

The efficiency of transfection of HEK cells with pCMV-KEa3/pCMV-KE34 was typical of standard efficiencies, whereas the efficiency of transfection of HEK cells with pCMV-KEa7 was below standard levels.

2. Stable Transfection of HEK Cells HEK cells were transfected using the calcium phosphate transfection procedure [Current Protocols in Molecular Biology, Vol. 1, Wiley Inter-Science, Supplement 14, Unit 9.1.1-9.1.9 (1990)). Ten-cm plates, each containing one-to-two million HEK cells were transfected with 1 ml of DNA/calcium phosphate precipitate containing 9.5 Hg pCMV-XEa3, 9.5 pg pCMV-XEB4 and 1 pg pSV2neo (as a selectable marker). After 14 days of growth in media containing 1 Hg/ml G418, colonies had formed and were individually isolated by using cloning cylinders. The isolates were subjected to limiting dilution and screened to identify those that expressed the highest level of nicotinic AChR, as described below.

3. Analysis of Transfectants a. Fluorescent indicator-based assays Activation of the ligand-gated nicotinic AChR by agonists leads to an influx of cations, including Ca+, through the receptor channel. Ca entry into the cell through the channel can induce release of calcium contained in intracellular stores. Monovalent cation entry into the cell through the channel can also result in an increase in cytoplasmic Ca levels through depolarization of the membrane and subsequent activation of voltage-dependent calcium channels. Therefore, methods of detecting transient increases in intracellular calcium concentration can be applied to the analysis of functional nicotinic AChR expression. One method for measuring intracellular calcium levels relies on calciumsensitive fluorescent indicators.

Calcium-sensitive indicators, such as fluo-3 (Catalog No. F-1241, Molecular Probes, Inc., Eugene, OR), are available ds acetoxymethyl esters which are menbrane permeable. When the acetoxymethyl ester form of the indicator enters a cell, the ester group is removed by cytosolic esterases, thereby trapping the free indicator in the cytosol. Interaction of the free indicator with calcium results in increased fluorescence of the indicator; therefore, an increase in the intracellular Ca 2. concentration of cells containing the indicator can be expressed directly as an increase in fluorescence.An automated fluorescence detection system for assaying nicotinic AChR has been described in commonly assigned pending US Patent Application No. 07/812,254 and corresponding PCT Patent Application No. US92/11090.

HEX cells that were transiently or stably cotransfected with DNA encoding a3 and ss4 subunits were analyzed for expression of functional recombinant nicotinic AChR using the automated fluorescent indicatorbased assay. The assay procedure was as follows.

Untransfected HEK cells (or HEK cells transfected with pCMV-T7-2) and HEK cells that had been co-transfected with pCMV-KEa3 and pCMV-XEB4 were plated in the wells of a 96-well microtiter dish and loaded with fluo-3 by incubation for 2 hours at 200C in a medium containing 20 pM fluo-3, 0.2% Pluronic F-127 in HBS (125 mM NaCl, 5 mM XCl, 1.8 mM CaC12, 0.62 mM MgSO4, 6 mM glucose, 20 mM HEPES, pH 7.4). The cells were then washed with assay buffer (i.e., HBS). The antagonist d-tubocurarine was added to some of the wells at a final concentration of 10 pM. The microtiter dish was then placed into a fluorescence plate reader and the basal fluorescence of each well was measured and recorded before addition of 200 pM nicotine to the wells. The fluorescence of the wells was monitored repeatedly during a period of approximately 60 seconds following addition of nicotine.

The fluorescence of the untransfected HEK cells (or HEK cells transfected with pCMV-T7-2) did not change after addition of nicotine. In contrast, the fluorescence of the co-transfected cells, in the absence of d-tubocurarine, increased dramatically after addition of nicotine to the wells. This nicotine-stimulated increase in fluorescence was not observed in co-transfected cells that had been exposed to the antagonist d-tubocurarine. These results demonstrate that the co-transfected cells express functional recombinant AChR that are activated by nicotine and blocked by d-tubocurarine.

b. a-Bunqarotoxin binding assays HEK293 cells transiently transfected with pCMV-KE&alpha;7 were analyzed for [125I]-&alpha;-bungarotoxin [BgTx] binding. Both whole transfected cells and membranes prepared from transfected cells were examined in these assays. Rat brain membranes were included in the assays as a positive control.

Rat brain membranes were prepared according to the method of Hampson et al. (1987) J. Neurochem 49:1209.

Membranes were prepared from the HEK cells transfected with pCMV-XEa7 and HEK cells transiently transfected with plasmid pUCl9 only (negative control) according to the method of Perez-Reyes et al. (1989) Nature 340:233.

Whole transfected and negative control cells were obtained by spraying the tissue culture plates with phosphate-buffered saline containing 0.1% (w/v) BSA. The cells were then centrifuged at low speed, washed once, resuspended in assay buffer (118 mM NaCl, 4.8 mM KC1, 2.5 mM Cad2, 1.2 mM MgSOn, 20 nM HEPES, 0.1% (w/v)BSA, 0.05% (w/v) bacitracin and 0.5 mM PMSF, pH 7.5) and counted.

Specific bindinbg of [125I]-&alpha;-BgTx to rat brain membranes was determined essentially as described by Marks et al. (1982) Molec. Pharmacol. 22:554-564, with several modifications. The membranes were washed twice in assay buffer. The assay was carried out in 12 x 75 mm polypropylene test tubes in a total volume of 0.5 ml assay buffer. The membranes were incubated with 10 nM [125I]-&alpha;-BgTx (New England Nuclear, Boston, MA) for one hour at 370C. The assay mixtures were then centrifuged at 2300 x g for 10 minutes at 40C. The supernatant was decanted and the pellets were washed twice with 2 ml aliquots of ice-cold assay buffer. The supernatants were decanted again and the radioactivity of the pellets was measured in a y-counter.Non-specific binding was determined in the presence of 1 pM unlabeled a-BgTx.

Specific binding was determined by subtracting nonspecific binding from total binding. Specific binding of [125I]-&alpha;-BgTx to membranes prepared from transfected and negative control cells was determined as described for determining specific binding to rat brain membranes except that the assay buffer did not contain BSA, bacitracin and PMSF. Specific binding of [125I]-&alpha;-BgTx to transfected and negative control whole cells was determined basically as described for determining specific binding to rat brain membranes.

[125I]-&alpha;-BgTx binding was evaluated as a function of membrane concentration and as a function of incubation time. [125I]-&alpha;-BgTx binding to rat brain membranes increased in a linear fashion with increasing amounts of membrane (ranging between 25-500 g). The overall signal-to-noise ratio of binding (i.e., ratio of total binding to non-specific binding) was 3:1. Although some binding of [125I]-&alpha;-BgTx to transfected cell membranes was detected, it was mostly non-specific binding and did not increase with increasing amounts of membrane. [l25l3-a-BgTx binding to the transfectants and negative control cells appeared to be similar.

125 To monitor [ I]-a-BgTx binding to rat brain membranes and whole transfected and negative control cells, 300 g of membrane or 500,000 cells were incubated with 1 nM or 10 nM [X25I)-a-BgTx, respectively, at 370C for various times ranging from 0-350 min. Aliquots of assay mixture were transferred to 1.5 ml microfuge tubes at various times and centrifuged. The pellets were washed twice with assay buffer. [125I]-&alpha;-BgTx binding to rat brain membranes increased with time and was maximal after three hours. The binding profiles of the transfected and negative control cells were the same and differed from that of rat brain membranes.

Example 5 Characterization of Cell Lines Expressing nNAChRs Recombinant cell lines generated by transfection with DNA encoding human neuronal nicotinic AChRs, such as those described in Example 3, can be further characterized using one or more of the following methods.

A. Northern or slot blot analysis for exDression of a- and/or B-subunit encoding messaqes Total RNA is isolated from -1X107 cells and 10-15 ;ig of RNA from each cell type is used for northern or slot blot hybridization analysis. The inserts from human neuronal NAChR-encoding plasmids can be nicktranslated and used as probe. In addition, the ss-actin gene sequence (Cleveland et al. (1980) Cell 20:95-105) can be nick-translated and used as a control probe on duplicate filters to confirm the presence or absence of RNA on each blot and to provide a rough standard for use in quantitating differences in a- or specific mRNA levels between cell lines.Typical northern and slot blot hybiidization and wash conditions are as follows: hybridization in 5x SSPE, 5X Denhardt's solution, 50% formamide, at 420C followed by washing in 0.2x SSPE1 0.1% SDS, at 650C.

B. Nicotine-binding assay Cell lines generated by transfection with human neuronal nicotinic AChR a- or a- and 8-subunit-encoding DNA can be analyzed for their ability to bind nicotine, for example, as compared to control cell lines: neuronally-derived cell lines PC12 (Boulter et al., (1986), supra; ATCC tCRL1721) and IMR32 (Clementi, et al.

(1986); Int. J. Neurochem. 47:291-297; ATCC CCL127), and muscle-derived cell line BC3H1 (Patrick, et al., (1977); J. Biol. Chem. 252:2143-2153). Negative control cells (i.e., host cells from which the transfectants were prepared) are also included in the assay. The assay is conducted as follows: Just prior to being assayed, transfected cells are removed from plates by scraping. Positive control cells used are PC12, BC3H1, and IMR32 (which had been starved for fresh media for seven days). Control cell lines are removed by rinsing in 370C assay buffer (50mM Tris/HCl, 1 mM MgCl2, 2 mM CaC12, 120 mM NaCl, 3 mM EDTA, 2 mg/ml BSA and 0.1 % aprotinin at pH7.4). The cells are washed and resuspended to a concentration of 1 x 106/250 l. To each plastic assay tube is added 250 l of the cell solution, 15 nM 3H-nicotine, with or without 1 mM unlabeled nicotine, and assay buffer to make a final volume of 500 p1. The assays for the transfected cell lines are incubated for 30 min at room temperature; the assays of the positive control cells are incubated for 2 min at 10C. After the appropriate incubation time, 450 p1 aliquots of assay volume are filtered through Whatman GF/C glass fiber filters which has been pretreated by incubation in 0.05% polyethyleneimine for 24 hours at 40C. The filters are then washed twice, with 4 ml each wash, with ice cold assay buffer. After washing, the filters are dried, added to vials containing 5 ml scintillation fluid and radioactivity is measured.

S' C. Rb ion-flux assay The ability of nicotine or nicotine agonists and antagonists to mediate the influx of gRb into transfected and control cells has been found to provide an indication of the presence of functional AChRs on the cell surface. The 86Rb ion-flux assay is conducted as follows: 1. The night before the experiment, cells are plated at 2 x 106 per well (i.e., 2 ml per well) in a 6well polylysine-coated plate.

2. The culture medium is decanted and the plate washed with 2 ml of assay buffer (50 mM HEPES, 260 mM sucrose, 5.4 mM KC1, 1.8 mM CaCl2, 0.8 mM MgSOX, 5.5. mM glucose) at room temperature.

3. The assay buffer is decanted and 1 ml of assay buffer, containing 3 pCi/ml MRb, with 5 mM ouabain and agonist or antagonist in a concentration to effect a maximum response, is added.

4. The plate is incubated on ice at 10C for 4 min.

5. The buffer is decanted into a waste container and each well was washed with 3 ml of assay buffer, followed by two washes of 2 ml each.

6. The cells are lysed with 2 x 0.5 ml of 0.2% SDS per well and transferred to a scintillation vial containing 5 ml of scintillation fluid.

7. The radioactivity contained in each vial is measured and the data calculated.

Positive control cells provided the following data in this assay: PC12 IMR32 Maximum Maximum ECso response ECso response Agonist nicotine 52 pM 2.1X' 18 pM 7.7X CCh* 35 M 3.3xb 230 M 7.6Xc cytisine 57 pM 3.6Xd 14 M lOX' Antagonist d.tubocurarine 0.81 M 2.5 M mecamylamine 0.42 M 0.11 M hexamethonium ndf 22 M atropine 12.5 pM 43 pM CCh - carbamylcholine o 200pM nicotine b 300pM CCh 3mM cch d lmM cytisine # 100 M cytisine f nd - not determined D.Electrophysiological Analysis of Mammalian Cells Transfected with Human Neuronal Nicotinic AChR Subunit-encoding DNA Electrophysiological measurements may be used to assess the activity of recombinant receptors or to assess the ability of a test compound to potentiate, antagonize or otherwise modulate the magnitude and duration of the flow of cations through the ligand-gated recombinant AChR. The function of the expressed neuronal AChR can be assessed by a variety of electrophysiological techniques, including two-electrode voltage clamp and patch clamp methods. The cation-conducting channel intrinsic to the AChR opens in response to acetylcholine (ACh) or other nicotinic cholinergic agonists, permitting the flow of transmembrane current carried predominantly by sodium and potassium ions under physiological conditions.This current can be monitored directly by voltage clamp techniques. In preferred embodiments, transfected mammalian cells or injected oocytes are analyzed electrophysiologically for the presence of AChR agonist-dependent currents.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

Summary of Sequences Sequence ID No. 1 is a nucleotide sequence encoding an a2 subunit of human neuronal nicotinic acetylcholine receptor.

Sequence ID No. 2 is the amino acid sequence deduced from the nucleotide sequence encoding an 22 subunit of human neuronal nicotinic acetylcholine receptor set forth in Sequence ID No. 1.

Sequence ID No. 3 is a nucleotide sequence encoding an a3 subunit of human neuronal nicotinic acetylcholine receptor.

Sequence ID No. 4 is the amino acid sequence deduced from the nucleotide sequence encoding an subunit of human neuronal nicotinic acetylcholine receptor set forth in Sequence ID No. 3.

Sequence ID No. 5 is a nucleotide sequence encoding an an subunit of a human neuronal nicotinic acetylcholine receptor.

Sequence ID No. 6 is the amino acid sequence deduced from the nucleotide sequence encoding an subunit of a human neuronal nicotinic acetylcholine receptor set forth in Sequence ID No. 5.

Sequence ID No. 7 is a nucleotidx sequence encoding an &alpha;7 subunit of human neuronal nicotinic acetylcholine receptor.

Sequence ID No. 8 is the amino acid sequence deduced from the nucleotide sequence encoding an a7 subunit of human neuronal nicotinic acetylcholine receptor set forth in Sequence ID No. 7.

Sequence ID No. 9 is a nucleotide sequence encoding a ss2 subunit of human neuronal nicotinic acetylcholine receptor.

Sequence ID No. 10 is the amino acid sequence deduced from the nucleotide sequence encoding a ss2 subunit of human neuronal nicotinic acetylcholine receptor set forth in Sequence ID No. 9.

Sequence ID No. 11 is a nucleotide sequence encoding a ss4 subunit of human neuronal nicotinic acetylcholine receptor.

Sequence ID No. 12 is the amino acid sequence deduced from the nucleotide sequence encoding a ss subunit of human neuronal nicotinic acetylcholine receptor set forth in Sequence ID No. 11.

SEQUENCE LISTINC (1) GENERAL INFORMATION: (i) APPLICANT: Elliot, Kathryn J.

Ellis, Steven B.

Harpold, Michael H.

(it) TITLE OF INVENTION: HUMAN NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR COMPOSITIONS AND METHODS EMPLOYING SAME (iii) NUMBER OF SEQUENCES: 12 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark (B) STREET: 444 South Flower Street, Suite 2000 (C) CITY: Los Angeles (D) STATE: CA (E) COUNTRY: USA (F) ZIP: 90071 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTUARE: Patentln Release &num;1.0, Version &num;1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUHBER: (B) FILING DATE: 08-MAR-1994 (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/028.031 (B) FILING DATE: 08-MAR-1993 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Reiter, Stephen E.

(B) REGISTRATION NUMBER: 31,192 (C) REFERENCE/DOCKET NUMBER: FP41 9714 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 619.546-4737 (B) TELEFAX: 619-546-9392 (2) lNFORMATlON FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2277 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 166..1755 (D) OTHER INFORMATION: /product- "ALPHA#2 SUBUNIT" (xi) SEQUENCE DESCRIPTION:SEQ ID NO:1: CAATGACCTG TTTTCTTCTG TAACCACAGG TTGGGTGGTG AGAGGAASCY TCGCAGAATC 60 CACCACAATC CTCACAGAAT CCAGCAGCAG CTCTGCTCGG GACATGGTCC ATGGTGCAAC 120 CCACAGCAAA GCCCTGACCT GACCTCCTCA TGCTCAGGAG AACCCATGCC CCCCTCCTGT 180 CCTGTGTTCC TGTCCTTCAC AAAGCTCAGC CTGTGGTGGC TCCTTCTGAC CCCAGCAGGT 240 GGAGAGGAAG CTAAGCGCCC ACCTCCCAGC GCTCCTGGAG ACCCACTCTC CTCTCCCAGT 300 CCCACGGCAT TGCCGCAGGG AGGCTCGCAT ACCGAGACTG AGGACCGGCT CTTCAAACAC 360 CTCTTCCCGG GCTACAACCC CTGGCCGCGC CCGGTGCCCA ACACTTCAGA CCTGCTGATT 420 GTGCGCTTTG GACTGTCCAT CGGTGAGCTG ATGGATGTGG ATGAGAAGAA CCAAATGATG 480 ACCACCAACC TCTGGCTAAA ACACGAGTCG ACCGACTACA AACTGGGGTG GAACCCCGCT 540 GATTTTGGCA ACATCACATC TCTCACCGTC CCTTCTGACA TCATCTCGAT CCCCGACATT 600 GTTCTCTACA ACAATGCACA TGGGGAGTTT GCAGTGACCC ACATGACCAA GGCCCACCTC 660 TTCTCCACGG GCACTCTGCA CTGCGTGCCC CCCGCCATCT ACAAGAGCTC CTGCAGCATC 720 GACGTCACCT TCTTCCCCTT CGACCACCAC AACTGCAACA TCAACTTTCC CTGGTGGACT 780 TATGACAAGG CCAAGATGGA GGTGGAGCAG ATGGAGCAGA GTGTGGACCT GAAGGACTAC 840 TGGGAGAGGG GCCAGTGGGC CATGGTCAAT GCCAGGGGCA CCTACAACAG CAAGAACTAC 900 CACTCCTGCG CCCAGATCTA CCCCGACCTC ACCTACGCCT TCGTCATCCG GCGGCTGCGG 960 CTCTTCTACA CCATCAACCT CATCATCCCC TGCCTGCTCA TCTCCTGCCT CACTGTGCTG 1020 GTCTTCTACC TCCCCTCCCA CTCCGGCGAG AACATCACCC TGTGCATTTC CCTGCTCCTC 1080 TCACTCACCC TCTTCCTGCT GCTCATCACT CAGATCATCC CGTCCACCTC GCTGCTCATC 1140 CCGCTGATCG GCGAGTAGCT GCTGTTCACC ATGATCTTCG TCACCCTGTC CATCGTCATC 1200 ACCCTCTTCG TGCTCAATCT GCACCACCGC TCCCCCACCA CCCACACCAT GCCCCACTGG 1260 GTGCGGGGGG CCCTTCTGGG CTGTGTGCCC GGGTGGCTTC TGATGAAGGG GCCCCCACCA 1320 CCCCTGCAGC TCTCCCACCC CCTACTCCTG AAGCTCAGCC CCTCTTATCA CTGGCTCCAC 1380 AGCAACCTGG ATGCCGAGGA GAGGGAGCTC GTGCTGGACC AGGAGGACAG ATGGGCATGT 1440 GCAGCTCATG TGGCCCCCTC TGTCCGCACC CTCTGCAGCC ACGCCCACCT GCACTCTCCG 1500 GCCTCAGGTC CCAAGCCTGA CGCTCTCCTG CACGACCCTG AGCTGCTGCT ATCACCCCAC 1560 ATCCACAAGG CACTGGAAGG TGTGCACTAC ATTCCCCACC ACCTGCCCTC TGAGGATGCT 1620 GACTCTTCGG TGAAGGAGGA CTGGAAGTAT GTTGGCATGG TCATGGACAG GATCTTCCTC 1680 TCGCTCTTTA TCATCGTCTG CTTCCTCGGC ACCATCCCCC TCTTTCTGCC TCCGTTCCTA 1740 CCTGGAATGA TCTGACTGCA CCTCCCTCGA GCTGGCTCCC AGGGCAAAGG GGAGGGTTCT 1800 TCGATCTCCA ACGGCTTTCA ACAATGTTTA GATTTGGAGA TGAGCCCAAA GTGCCAGGGA 1860 GAACAGCCAG GTGAGGTGGG AGGTTGGAGA GCCAGGTGAG GTCTCTCTAA GTCAGGCTGG 1920 GCTTCAACTT TGGAGTCTGT CCGAGTTTGC AGGCTCCTCA CCTGTATGCT CCAGCACGGC 1980 AGTAATAAGG GCTCTTCCCC AAGCGCACCA ACCGCCACCC ACCCCCTGCA CCTCATGTGC 2040 AGGTACAGGG CAGATCTTCC CTACCGGGGA GGGATGGATG GTTGGATACA GGTGGCTGGG 2100 CTATTCCATC CATCTGCAAG CACATTTGAC CCTCCAGGCT TCTCCTTGAC CTCATTCCTC 2160 TCCTTCCTTG CTCCAAAATG GCTCTGCACC AGCCGGCCCC CAGGAGGTCT GGCAGAGCTG 2220 AGAGCCATGG CCTGCAGGGG CTCCATATGT CCCTACGCGT GCAGCAGGCA AACAAGA 2277 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 529 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION:SEQ ID NO:2: Met Cly Pro Ser Cys Pro Val Phe Leu Ser Phe Thr Lys Leu Ser Leu 1 5 10 15 Trp Trp Leu Leu Leu Thr Pro Ala Gly Cly Clu Glu Ala Lys Arg Pro 20 25 30 Pro Pro Arg Ala Pro Gly Asp Pro Leu Ser Ser Pro Ser Pro Thr Ala 35 40 45 Leu Pro Gin Cly Cly Ser His Thr Glu Thr Clu Asp Arg Leu Phe Lys 50 55 60 His Leu Phe Arg Gly Tyr Asn Arg Trp Ala Arg Pro Val Pro Asn Thr 65 70 75 80 Ser Asp Val Val Ile Val Arg Phe Gly Leu Ser Ile Ala Gln Leu lie 85 90 .95 Asp Val Asp Glu Lys Asn Gin Met Met Thr Thr Asn Val Trp Leu Lys 100 105 110 Gln Giu Trp Ser Asp Tyr Lys Leu Arg Trp Asn Pro Ala Asp Phe Gly 115 120 125 Asn Ile Thr Ser Leu Arg Val Pro Ser Giu Met Ile Trp Ile Pro Asp 130 135 140 Ile Val Leu Tyr Asn Asn Ala Asp Gly Giu Phe Ala Val Thr His Met 145 150 155 160 Thr Lys Ala His Leu Phe Ser Thr Gly Thr Val His Trp Val Pro Pro 165 170 175 Ala Ile Tyr Lys Ser Ser Cys Ser Ile Asp Val Thr Phe Phe Pro Phe 180 185 190 Asp Gin Gin Asn Cys Lys Met Lys Phe Gly Ser Trp Thr Tyr Asp Lys 195 200 205 Ala Lys Ile Asp Leu Clu Gln Met Glu Gln Thr Val Asp Leu Lys Asp 210 215 220 Tyr Trp Glu Ser Gly Glu Trp Ala Ile Val Asn Ala Thr Cly Thr Tyr 225 230 235 240 Asn Ser Lys Lys Tyr Asp Cys Cys Ala Glu Ile Tyr Pro Asp Val Thr 245 250 255 Tyr Ala Phe Val Ile Arg Arg Leu Pro Leu Phe Tyr Thr Ile Asn Leu 260 265 270 Ile Ile Pro Cys Leu Leu Ile Ser Cys Leu Thr Val Leu Val Phe Tyr 275 280 285 Leu Pro Ser Asp Cys Cly Ciu Lys lie Thr Leu Cys Ile Ser Val Leu 290 295 300 Leu Ser Leu Thr Val Phe Leu Leu Leu Ile Thr Giu Ile Ile Pro Ser 305 310 315 320 Thr Ser Leu Val Ile Pro Leu lie Gly Ciu Tyr Leu Leu Phe Thr Met 325 330 335 Ile Phe Val Thr Leu Ser Ile Val Ile Thr Val Phe Val Leu Asn Val 340 345 350 His His Arg Ser Pro Ser Thr His Thr Met Pro His Trp Val Arg Gly 355 360 365 Ala Leu Leu Gly Cys Val Pro Arg Trp Leu Leu Met Asn Arg Pro Pro 370 375 380 Pro Pro Val Glu Leu Cys His Pro Leu Arg Leu Lys Leu Ser Pro Ser 385 390 395 400 Tyr His Trp Leu Gl Ser Asn Val Asp Ala Giu Glu Arg Glu Val Val 405 410 415 Val Glu Glu Glu Asp Arg Trp Ala Cys Ala Gly His Val Ala Pro Ser 420 425 430 Val Gly Thr Leu Cys Ser His Gly His Leu His Ser Gly Ala Ser Gly 435 440 445 Pro Lys Ala Glu Ala Leu Leu Gln Clu Cly Glu Leu Leu Leu Ser Pro 450 455 460 His Met Gln Lys Ala Leu Glu Gly Val His Tyr Ile Ala Asp His Leu 465 470 475 480 Arg Ser Giu Asp Ala Asp Ser Ser Val Lys Clu Asp Trp Lys Tyr Val 485 490 495 Ala Met Val lie Asp Arg Ile Phe Leu Trp Leu Phe Ile Ile Val Cys 500 505 510 Phe Leu Gly Thr lie Gly Leu Phe Leu Pro Pro Phe Leu Ala Gly Met 515 520 525 Ile (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1757 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOCY: both (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 39..1553 (D) OTHER INFORMATlON: /product- "ALPHA-3 SUBUNlT" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: CCGACCCTCC CCGTCCGCGG CCAGCCCCGC CACCAGCCAT GCGCTCTGCC CCGCTCTCCC 60 TCCOCCTGGC GCTCTCCCCG CCCCCGCTGC TGCTCCTGCT GCTCTCTCTC CTCCCAGTGC 120 CCAGGGCCTC ACAGGCTGAC CACCGTCTAT TTGAGCGGCT GTTTGAAGAT TACAATGACA 180 TCATCCGGCC TGTAGCCAAC GTGTCTGACC CAGTCATCAT CCATTTCCAC GTGTCCATGT 240 CTCAGCTGGT GAAGGTGGAT GAAGTAAACC AGATCATGGA GAGGAACCTG TGGCTCAAGC 300 AAATCTGGAA TGACTACAAG CTGAAGTGGA ACCCCTCTGA CTATGGTGGG GCACAGTTCA 360 TGCGTGTCCC TGCACAGAAG ATCTGGAAGC CAGACATTGT GCTGTATAAC AATGCTGTTG 420 GGGATTTCCA GGTGGACGAC AAGACCAAAG CCTTACTCAA GTACACTGGG GAGGTGACTT 480 GGATACCTCC GGCCATCTTT AAGAGCTCCT GTAAAATCGA CCTGACCTAC TTCCCGTTTG 540 ATTACCAAAA CTGTACCATG AAGTTCGGTT CCTGGTCCTA CGATAAGGCG AAAATCGATC 600 TGCTCCTCAT CGGCTCTTCC ATGAACCTCA AGGACTATTG GGAGAGCGGC GAGTGGGCCA 660 TCATCAAAGC CCCACGCTAC AAACACGACA TCAAGTACAG CTGCTGCGAG GACATCTACC 720 CCGACATCAC ATACTCGCTG WWCATCCGGC GGCTGTCGTT GTTCTACACC ATCAWCCTCA 780 TCATCCGCTG GCTGATCATC TCCTTCATCA CTGTGGTCGT CTCCTACCTG CCCTCCGACT 840 GCGGCGAGAA GGTGACCCTG TGYATTTCTG TCCTCCTCTC CCTGAGGGTG TTTCTCCTGG 900 TGATCACTGA GACCATCCCT TCCACCTGGC TGGTCATCCC CCTGATTGGA GAGTAGGTGC 960 TGWWCACCAT GATTTGTCTA ACCTTGTCCA TCGACATCAC CGTCTGCGTG CTCAACGTGC 1020 ACTACAGAAC CCCGAGGACA CACACAATGC CCTCATGGGT GAAGACTGTA TTCTTGAMCC 1080 TGCTCCCCAG GGTCATGTUC ATCACCAGGC CAACAACCAA CGAGGGCAAC GCTCAGAAGC 1140 CCACCCCCCT CTACGGTGCC GAGCTCTCAA ATCTGAATTG CTTCAGCGGC GCAGAGTCCA 1200 AAGGCTGCAA GGAGGGCTAC CCCTGGGAGG ACGGGATGTG TGGTTACTGC CACCACCGCA 1260 GGATAAAAAT CTCCAATTTC AGTGCTAACC TCACGAGAAG CTCTAGTTCT GAATCTGTTG 1320 ATGCTGTGCT GTCCCTCTCT GCTTTGTCAC CAGAAATCAA AGAAGCCATC CAAAGTGTCA 1380 AGTATATTGC TCAAAATATG AAAGCACAAA ATGAAGCCAA AGAGATTCAA GATGATTGGA 1440 AGTATGTTGC CATGGTGATT GATGGTATTT TTCTGTGGGT TTTCACCCTG GTGTGCATTC 1500 TAGGGACAGC AGGATTGTTT CTGCAACCCC TGATGGGCAG GGAAGATGCA TAAGCACTAA 1560 GCTGTGTGCC TGCCTGGGAG ACTTCCTTGT GTCAGGGCAG GAGGAGGCTG CTTCCTAGTA 1620 AGAACGTACT TTCTCTTATC AAGCTACCAG CTTTGTTTKK GGCATTTCGA GGTTTACTTA 1680 TTTTCCACTT ATCTTGGAAT CATGCCG@NN NNAAATGTCA AGAGTATTTA TTACCGATAA 1740 ATGAACATTT AACTAGC 1757 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENCTH: 504 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION:SEQ ID NO:4: Met Cly Ser Gly Pro Leu Ser Leu Pro Leu Ala Leu Ser Pro Pro Arg 1 5 lO 15 Leu Leu Leu Leu Leu Leu Ser Leu Leu Pro Val Ala Arg Ala Ser Giu 20 25 30 Ala Clu His Arg Leu Phe Clu Arg Leu Phe Clu Asp Tyr Asn Glu Ile 35 40 45 Ile Arg Pro Val Ala Asn Val Ser Asp Pro Val Ile Ile His Phe Ciu 50 55 60 Val Ser Met Ser Gin Leu Val Lys Val Asp Clu Val Asn Gln Ile Met 65 70 75 80 Glu Thr Asn Leu Trp Leu Lys Gln Ile Trp Asn Asp Tyr Lys Leu 85 90 95 Trp Asn Pro Ser Asp Tyr Gly Gly Ala Glu Phe Met Arg Val Pro Ala 100 105 110 Gin Lys lie Trp Lys Pro Asp Ile Val Leu Tyr Asn Asn Ala Val Gly 115 120 125 Asp Phe Gin Val Asp Asp Lys Thr Lys Ala Leu Leu Lys Tyr Thr Gly 130 135 140 Glu Val Thr Trp lie Pro Pro Ala Ile Phe Lys Ser Ser Cys Lys lie 145 150 155 160 Asp Val Thr Tyr Phe Pro Phe Asp Tyr Gin Asn Cys Thr Met Lys Phe 165 170 175 Gly Ser Trp Ser Tyr Asp Lys Ala Lys lie Asp Leu Val Leu Ile Gly 180 185 190 Ser Ser Met Asn Leu Lys Asp Tyr Trp Glu Ser Gly Glu Trp Ala Ile 195 200 205 Ile Lys Ala Pro Gly Tyr Lys His Asp Ile Lys Tyr Ser Cys Cys Clu 210 215 220 Glu Ile Tyr Pro Asp Ile Thr Tyr Ser Leu Xaa Ile Arg Arg Leu Ser 225 230 235 240 Leu Phe Tyr Thr Ile Xaa Leu Ile Ile Arg Trp Leu Ile Ile Ser Phe 245 250 255 lie Thr Val Val Val Ser Tyr Leu Pro Ser Asp Cys Gly Ciu Lys Val 260 265 270 Thr Leu Cys Ile Ser Val Leu Leu Ser Leu Thr Val Phe Leu Leu Val 275 280 285 Ile Thr Glu Thr Ile Pro Ser Thr Ser Leu Val Ile Pro Leu Ile Gly 290 295 300 Glu Tyr Leu Leu Xaa Thr Met Ile Cys Val Thr Leu Ser Ile Asp Ile 305 310 315 320 Thr Val Cys Val Leu Asn Val His Tyr Arg Thr Pro Thr Thr His Thr 325 330 335 Met Pro Ser Trp Val Lys Thr Val Phe Leu Xaa Leu Leu Pro Arg Val 340 345 350 Met Xaa Met Thr Arg Pro Thr Ser Asn Giu Gly Asn Ala Gin Lys Pro 355 360 365 Arg Pro Leu Tyr Gly Ala Giu Leu Ser Asn Leu Asn Cys Phe Ser Arg 370 375 380 Ala Giu Ser Lys Cly Cys Lys Glu Gly Tyr Pro Cys Gin Asp Gly Met 385 390 395 400 Cys Gly Tyr Gys His His Arg Arg Ile Lys Ile Ser Asn Phe Ser Ala 405 410 415 Asn Leu Thr Arg Ser Ser Ser Ser Glu Ser Val Asp Ala Val Leu Ser 420 425 430 Leu Ser Ala Leu Ser Pro Glu Ile Lys Giu Ala Ile Gln Ser Val Lys 435 440 445 Tyr lie Ala Glu Asn Met Lys Ala Gln Asn Glu Ala Lys Glu Ile Gin 450 455 460 Asp Asp Trp Lys Tyr Val Ala Met Val lie Asp Arg Ile Phe Leu Trp 465 470 475 480 Val Phe Thr Leu Val Cys lie Leu Gly Thr Ala Gly Leu Phe Leu Gin 485 490 495 Pro Leu Met Ala Arg Ciu Asp Ala 500 (2) INFORMATION FOR'SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2363 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 173..2056 (D) OTHER INFORMATION: /product- "ALPHA-4 SUBUNIT" (xi) SEQUENCE DESCRIPTION:SEQ ID NO:5: GCGCTCGCTG CGCCGCCCCC GCCGCNCCGC GCGCCACAGG ACAACGCGAN CCGGGCCCGG 60 CGGCCGAAGC GGCCCGCGAG GCGCGGGAGG CATGAAGTTG GGCGCGCACG GGCCTCGAAG 120 CGGCGGGGAG CCCGGAGCCG CCCGCATCTA GACCCCCCCA GGTGCCTGCC CCATCCAGCT 180 ACCGGGCCCC GCAGCGCCCC CGCTCCTCCC CCCGCTGCTC CTGCTTCTCG CCACCCGCCT 240 CCTGCGCGCC AGCAGCCATG TGGAGACCCG GGCCCACGCC GAGGAGCGGC TCCTGAAGAA 300 ACTCTTCTCC GGTTACAACA AGTGGTCCCG ACCCGTGGCC AACATCTCGG ACGTGGTGCT 360 CGTCCGCTTC GGCCTGTCCA TCGCTCAGCT CATTGACGTC CATCAGAAGA ACCAGATGAT 420 GACCAGGAAC GTGTGGGTGA AGCAGGAGTG GCACGACTAC AAGCTGCGCT GGGACCCAGC 480 TGACTATGAG AATGTCACCT CCATCCGCAT CCCCTCCGAG CTCATCTGGC GGCCGGACAT 540 CGCCCTCTAC AACAATGCTG ACGGGGACTT CGCGGCCACC CACCTGACCA AGGCCCACCT 600 GTTCCATGAC CGGCGCGTCC ACCGCACTCC CCCGGCCATT TACAACACCT CCTGCACCAT 660 CGACGTCACC TTCTTCCCCT TCGACCAGCA GAACTGCACC ATGAAATTCG GCTCCTGGAC 720 CTAGGACAAG GCCAAGATCG ACCTGGTGAA CATGCACAGC CGCGTGGACC AGCTGGACTT 780 CTGGGAGAGT GGCGAGTGGC TCATCTCGGA CGCCGTGGGC ACCTACAACA CCAGGAAGTA 840 CCAGTCCTCC GCCGAGATCT ACCCCCACAT CACCTATCCC TACCCCATCC GCCCCCTCCC 900 CCTCTTCTAC ACCATCAACC TCATCATCCC CTCGCTCCTC ATCTCCTCCC TCACCCCCCT 960 GGTCTTCTAC CTGCCCTCCG AGTGTGGCGA GAAGATCACG CTGTGCATCT CCGTGCTGCT 1020 GTCCCTCACC CTCTTCCTGC TGCTCATCAC CGAGATCATC CCGTCCACCT CACTGGTCAT 1080 CCCACTCATC GGCCAGTAGC TGCTGTTCAC CATGATCTTC GTCACCCTGT CCATCGCCAT 1140 CACGGTCTTC GTGCTGAACG TGCACCACCG CTCGCCACGG ACGCACACCA TGCCCACCTG 1200 GGTACGCAGG GTCTTCCTGG ACATCGTGCC ACGCCTGCTC CTCATGAAGC GGCCGTGCGT 1260 GGTCAAGGAC AATTGCCGGC GGCTCATGGA GTCCATGCAT AAGATGGCCA GTGGGCCGCG 1320 CTTCTGGCCC GAGCCAGAAG GGGAGCCCCC TGCCACGAGC GGCACCCAGA GCCTGCACCC 1380 TCCCTCACCC TCCTTCTGCG TCCCCCTGCA TGTGCCGGCT GAGCCTGGGC CTTCCTGCAA 1440 GTCACCCTCC GACCAGCTCC CTCCTCAGCA GCCCCTGGAA GCTGAGAAAG CCAGCCCCCA 1500 CCCCTCGCCT GGACCCTGCC GCCCGCCCCA CGGCACCCAG GCACCAGGGC TGGCCAAAGC 1560 GAGGTCCCTC AGCGTCCAGC ACATGTCCAG CCCTGGCGAA GGGGTGGAAG GCGGCGTCCG 1620 GTGCCGGTCT CGGAGCATCC AGTACTGTGT TCCCCGAGAC GATGCCGCCC CCGAGGCAGA 1680 TGGCCAGGCT GCCGGCGCCC TGGCCTCTCG CAACAGCCAC TCGGCTGAGC TCCCACCCCC 1740 AGACCAGCCC TCTCCGTGCA AATGCACATG CAAGAAGGAG CCCTCTTCGG TGTCCCCGAG 1800 CGCCACGGTC AAGACCCGCA GCACCAAAGC GCCGCCGCCG CACCTGCCCC TGTCGCCGGC 1860 CCTGAGCCGG GCGGTGGAGG GCGTCCAGTA CATTGCAGAC CACCTGAAGG CCCAAGACAC 1920 ACACTTCTCG GTGAAGGAGG ACTGGAAGTA CGTGGCCATG GTCATCGACC GCATCTTCGT 1980 CTGGATGTTC ATCATCGTCT GCCTGCTGGG GACGGTGGGC CTCTTCCTGC CGCCCTGGCT 2040 GGCTGGCATG ATCTAGGAAG GGACCGGGAG CCTGCGTGGC CTGGGGCTGC CGYGCACGGG 2100 GCCAGCATCC ATGCGGCCGG CCTGGGGCCG GCCTGCCTTC TCCCTGGACT CTGTCGGGGC 2160 ACACGTTTGC CAAATTTTCC TTCCTGTTCT GTGTCTCCTG TAAGACGGCC TTGGACGGCG 2220 ACACCGCCTC TGGGGAGACC GAGTGTGGAG CTGCTTCCAG TTGGACTCTS GCCTCAGNAG 2280 GCAGCGGCTT GGAGCAGAGG TGGGGGTCCC CGCCTYCTAC CTGCAGGACT CGGGCTAAGT 2340 CCAGCTCTCC CCCTGCGCAG CCC 2363 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS:: (A) LENGTH: 627 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Met Giu Leu Gly Gly Pro Gly Ala Pro Arg Leu Leu Pro Pro Leu Leu 1 5 10 15 Leu Leu Leu Gly Thr Gly Leu Leu Arg Ala Ser Ser His Val Giu Thr 20 25 30 Arg Ala His Ala Glu Glu Arg Leu Leu Lys Lys Leu Phe Ser Gly Tyr 35 40 45 Asn Lys Trp Ser Arg Pro Val Ala Asn Ile Ser Asp Val Val Leu Val 50 55 60 Arg Phe Gly Leu Ser Ile Ala Gin Leu Ile Asp Val Asp Ciu Lys Asn 65 70 75 80 Gin Met Met Thr Thr Asn Val Trp Val Lys Gin Ciu Trp His Asp Tyr 85 90 95 Lys Leu Arg Trp Asp Pro Ala Asp Tyr Giu Asn Val Thr Ser Ile Arg 100 105 110 Ile Pro Ser Giu Leu Ile Trp Arg Pro Asp Ile Ala Leu Tyr Asn Asn 115 120 125 Ala Asp Gly Asp Phe Ala Ala Thr His Leu Thr Lys Ala His Leu Phe 130 135 140 His Asp Gly Arg Val Gin Arg Thr Pro Pro Ala Ile Tyr Lys Ser Ser 145 150 155 160 Cys Ser Ile Asp Val Thr Phe Phe Pro Phe Asp Gin Gin Asn Cys Thr 165 170 175 Met Lys Phe Gly Ser Trp Thr Tyr Asp Lys Ala Lys Ile Asp Le Val 180 185 190 Asn Met His Ser Arg Val Asp Gln Leu Asp Phe Trp Glu Ser Gly Glu 195 200 205 Trp Leu Ile Ser Asp Ala Val Cly Thr Tyr Asn Thr Arg Lys Tyr Glu 210 215 220 Cys Cys Ala Giu Ile Tyr Pro Asp Ile Thr Tyr Ala Tyr Ala Ile Arg 225 230 235 240 Arg Leu Pro Leu Phe Tyr Thr lie Asn Leu Ile Ile Pro Trp Leu Leu 245 250 255 Ile Ser Cys Leu Thr Ala Leu Val Phe Tyr Leu Pro Ser Glu Cys Gly 260 265 270 Giu Lys Ile Thr Leu Cys Ile Ser Val Leu Leti Ser Leu Thr Val Phe 275 280 285 Leu Leu Leu Ile Thr Glu Ile Ile Pro Ser Thr Ser Leu Val Ile Pro 290 295 300 Leu Ile Gly Ciu Tyr Leu Leu Phe Thr Met Ile Phe Val Thr Leu Ser 305 310 315 320 Ile Ala Ile Thr Val Phe Val Leu Asn Val His His Arg Ser Pro Arg 325 330 335 Thr His Thr Met Pro Thr Trp Val Arg Arg Val Phe Leu Asp Ile Val 340 345 350 Pro Arg Leu Leu Leu Met Lys Arg Pro Ser Val Val Lys Asp Asn Cys 3S5 360 365 Arg Arg Leu Ile Glu Ser Met His Lys Met Ala Ser Ala Pro Arg Phe 370 375 380 Trp Pro Giu Pro Glu Gly Glu Pro Pro Ala Thr Ser Gly Thr Gln Ser 385 390 39S 400 Leu His Pro Pro Ser Pro Ser Phe Cys Val Pro Leu Asp Val Pro Ala 405 410 415 Glu Pro Gly Pro Ser Cys Lys Ser Pro Ser Asp Gln Leu Pro Pro Gin 420 425 430 Gin Pro Leu Glu Ala Glu Lys Ala Ser Pro His Pro Ser Pro Cly Pro 435 440 445 Cys Arg Pro Pro His Gly Thr Gln Ala Pro Gly Leu Ala Lys Ala Arg 450 455 460 Ser Leu Ser Val Gln His Met Ser Ser Pro Gly Glu Ala Val Glu Cly 465 470 475 480 Gly Val Arg Cys Arg Ser Arg Ser lie Gin Tyr Cys Val Pro Arg Asp 485 490 495 Asp Ala Ala Pro Clu Ala Asp Cly Gin Ala Ala Cly Ala Leu Ala Ser 500 505 510 Arg Asn Ser His Ser Ala Glu Leu Pro Pro Pro Asp Gln Pro Ser Pro 515 520 525 Cys Lys Cys Thr Cys Lys Lys Glu Pro Ser Ser Val Ser Pro Ser Ala 530 535 540 Thr Val Lys Thr Arg Ser Thr Lys Ala Pro Pro Pro His Leu Pro Leu 545 550 555 560 Ser Pro Ala Leu Ser Arg Ala Val Glu Gly Val Gin Tyr Ile Ala Asp 565 570 575 His Leu Lys Ala Glu Asp Thr Asp Phe Ser Val Lys Glu Asp Trp Lys 580 585 590 Tyr Val Ala Met Val Ile Asp Arg Ile Phe Leu Trp Met Phe lie Ile 595 600 605 Val Cys Leu Leu Gly Thr Val Cly Leu Phe Leu Pro Pro Trp Leu Ala 610 615 620 Gly Met Ile 625 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1876 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 73..1581 (D) OTHER INFORMATION: /product- "ALPHA-7 SUBUNIT" (xi) SEQUENCE DESCRIPTION:SEQ ID NO:7: GGCCGCAGGC CCACGCCCGC GCCACACCCG AGACGTGGAG CGCCCCCCCT CGCTCCACCT 60 CCCCCACTCA ACATGCGCTG CTCGCCCGCA CCCGTCTGGC TGCCCCTGGC CGCCTCGCTC 120 CTGCACGTGT CCCTGCAAGG CGAGTTCCAG AGGAAGCTTT ACAAGGAGCT GGTCAAGAAC 180 TACAATCCCT TCCAGACGCC CGTCGCCAAT CACTCCCAAC CACTCACCCT CTACTTCTCC 240 CTGAGCCTCC TGCAGATCAT GGACGTGGAT CACAAGAACC AAGTTTTAAC CACCAACATT 300 TGGCTGCAAA TGTCTTGGAC AGATCACTAT TTACAGTGGA ATGTGTCAGA ATATCCAGGG 360 GTGAAGACTG TTCGTTTCCC AGATGGCCAG ATTTGGAAAC CAGACATTCT TCTCTATAAC 420 AGTGCTGATG AGCGCTTTGA CGCCACATTC GACACTAACG TGTTGGTGAA TTCTTCTGGG 480 CATTGCCAGT ACCTCCCTCC AGGCATATTC AACAGTTCCT GCTACATCGA TGTAGGCTGG 540 TTTCCCTTTG ATGTGCAGCA CTGCAAACTG AAGTTTCGGT CCTGGTCTTA CGGAGGCTGG 600 TCCTTGGATC TGCAGATGCA GGAGGCAGAT ATCAGTGGCT ATATCCCCAA TGGAGAATGC 660 GACCTAGTGG GAATCCCCGC CAAGAGGAGT GAAAGGTTCT ATGAGTGCTG CAAAGAGCCC 720 TACCCCGATG TCACCTTGAC AGTGACCATG CGCCGCAGGA CGCTCTACTA TGGCCTCAAC 780 CTGCTCATCC CCTGTGTGCT CATCTCCGCC CTCGCCCTGC TGGTGTTCCT GCTTCCTGCA 840 GATTCGGGGG AGAAGATTTC CCTGGGGATA ACAGTCTTAC TCTCTCTTAC CGTCTTCATG 900 CTGCTCGTGG CTGAGATCAT GCCCGCAACA TCCGATTCGG TACCATTGAT AGCCCAGTAC 960 TTCGCCAGCA CCATGATCAT CGTGCGCCTC TCCGTGGTCC TGACGGTGAT CGTGCTGCAG 1020 TACCACCACC ACGACCCCCA CGGGGGCAAG ATCCCCAAGT GGACCAGAGT CATCCTTCTG 1080 AACTGGTGCG CGTCGTTCCT SCCAATGAAG AGGCCCGCCG AGGACAACGT CCCCCCCGCC 1140 TGCCAGCACA AGCAGCGGCC CTGCAGCCTG GCCAGTGTGG AGATGAGCGC CGTGGCGCCC 1200 CCCCCCGCCA CCAACGGGAA CCTGCTGTAC ATCGCCTTCC GCGGCCTCGA CGGCGTGCAC 1260 TGTGTCCCGA CCCCCGACTC TCGCGTAGTC TGTGGCCGCA TGGCCTGCTC CCCCACGCAC 1320 GATGAGCACC TCCTGCACGG CGGGCAACCC CCCGAGGGGG ACCCGGACTT GGCCAAGATC 1380 CTGGAGGAGG TCCGCTACAT TGCCAATCGC TTCCGCTGCC AGGACGAAAG CCAGGCGGTC 1440 TGCAGCGAGT GGAAGTTCGC CGCCTGTGTG GTGGACCGCC TGTGCCTCAT GGCCTTCTCG 1500 GTCTTCACCA TCATCTCCAC CATCCGCATC CTGATGTCGG CTCCCAACTT CGTGGAGGCC 1560 GTGTCCAAAG ACTTTGCGTA ACCACGCCTG GTTCTGTACA TGTGGAAAAC TCACAGATGG 1620 GCAAGGCCTT TGGCTTGGCG AGATTTGGGG GTGCTAATCC AGGACAGCAT TACACGCCAC 1680 AACTCCACTG TTCCCTTCTG GCTGTCAGTC GTGTTGCTTA CGGTTTCTTT GTTACTTTAC 1740 GTAGTACAAT CTCAGCACTT TGTTTCATAT TCTCAGATGC GCTGATAGAT ATCCTTCCCA 1800 CATCCGTACC ATCGGTCAGC AGGGCCACTG AGTAGTCATT TTGCCCATTA GCCCACTGCC 1860 TCCAAAGCCC TTCGGA 1876 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 502 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (it) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION:SEQ ID NO:8: Met Arg Cys Ser Pro Gly Gly Val Trp Leu Ala Leu Ala Ala Ser Leu 1 5 10 15 Leu His Val Ser Leu Gln Gly Glu Phe Gln Arg Lys Leu Tyr Lys Glu 20 25 30 Leu Val Lys Asn Tyr Asn Pro Leu Giu Arg Pro Val Ala Asn Asp Ser 35 40 Cln Pro Leu Thr Val Tyr Phe Ser Leu Ser Leu Leu Gin Ile Net Asp 50 55 60 Val Asp Glu Lys Asn Gln Val Leu Thr Thr Asn Ile Trp Leu Gln 65 70 75 80 Ser Trp Thr Asp His Tyr Leu Cln Trp Asn Val Ser Glu Tyr Pro Cly 85 90 95 Val Lys Thr Val Arg Phe Pro Asp Gly Gin Ile Trp Lys Pro Asp Ile 100 105 110 Leu Leu Tyr Asn Ser Ala Asp Giu Arg Phe Asp Ala Thr Phe His Thr 115 120 125 Asn Val Leu Val Asn Ser Ser Gly His Cys Gin Tyr Leu Pro Pro Gly 130 135 140 Ile Phe Lys Ser Ser Cys Tyr Ile Asp Val Arg Trp Phe Pro Phe Asp 145 150 155 160 Val Gin His Cys Lys Leu Lys Phe Cly Ser Trp Ser Tyr Gly Cly Trp 165 170 175 Ser Leu Asp Leu Gln Het Gln Glu Ala Asp Ile Ser Gly Tyr Ile 180 185 190 Asn Gly Glu Trp Asp Leu Val Gly Ile Pro Gly Lys Arg Ser Glu 195 200 205 Phe Tyr Glu Cys Cys Lys Glu Pro Tyr Pro Asp Val Thr Phe Thr Val 210 215 220 Thr Met Arg Arg Arg Thr Leu Tyr Tyr Gly Leu Asn Leu Let flue Pro 225 230 235 240 Cys Val Leu Ile Ser Ala Leu Ala Leu Leu Val Phe Leu Leu Pro Ala 245 250 255 Asp Ser Gly Glu Lys Ile Ser Leu Gly Ile Thr Val Leu Leu Ser Leu 260 265 270 Thr Val Phe Met Leu Leu Val Ala Glu Ile Met Pro Ala Thr Ser Asp 275 280 285 Ser Val Pro Leu Ile Ala Gln Tyr Phe Ala Ser Thr Met Ile Ile Val 290 295 300 Cly Leu Ser Val Val Val Thr Val Ile Val Leu Gln Tyr His His His 305 310 315 320 Asp Pro Asp Gly Gly Lys Met Pro Lys Trp Thr Arg Val Ile Leu Leu 325 330 335 Asn Trp Cys Ala Trp Phe Leu Arg Met Lys Arg Pro Cly Glu Asp Lys 340 345 350 Val Arg Pro Ala Cys Gln His Lys Gln Arg Arg Cys Ser Leu Ala Ser 355 360 365 Val Giu Met Ser Ala Val Ala Pro Pro Pro Ala Ser Asn Gly Asn Leu 370 375 380 Leu Tyr Ile Gly Phe Arg Gly Leu Asp Gly Val His Cys Val Pro Thr 385 390 395 400 Pro Asp Ser Gly Val Val Cys Gly Arg Met Ala Cys Ser Pro Thr His 405 410 415 Asp Glu His Leu Leu His Cly Gly Gln Pro Pro Glu Gly Asp Pro Asp 420 425 430 Leu Ala Lys Ile Leu Glu Glu Val Arg Tyr Ile Ala Asn Arg Phe Arg 435 440 445 Cys Gin Asp Glu Ser Glu Ala Val Cys Ser Glu Trp Lys Phe Ala Ala 450 455 460 Cys Val Val Asp Arg Leu Cys Leu Met Ala Phe Ser Val Phe Thr Ile 465 470 475 480 Ile Cys Thr Ile Gly Ile Leu Met Ser Ala Pro Asn Phe Val Clu Ala 485 490 495 Val Ser Lys Asp Phe Ala 500 (2) INFORMATION FOR SEQ ID NO:9:: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2448 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (it) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 265..1773 (D) OTHER INFORMATION: /product- BETA.2 SUBUNIT (xi) SEQUENCE DESCRIPTION:SEQ ID NO:9: CTCCTCCCCC TCACCGTCCC AATTGTATTC CCTGGAAGAG CACCCGCAAA ACCCTCCCCC 60 TGCTCATACC AGGATAGGCA ACAACCTCGT TTCTCCTCGC AGCCGGCTCC CTCACCCCCA 120 GGAACCACCG CGGCGGCCGG CACCACCTGG ACCCAGCTCC AGGCGGGCGC GGCTTCAGCA 180 CCACGGACAG CGCCCCACCC GCGGCCCTCC CCCCGGCGGC GCGCTCCAGC CGGTGTAGGC 240 GAGGCAGCGA GCTATGCCCG CGGCATGGCC CGGCGCTGCG GCCCCGTGGC GCTGCTCCTT 300 GGCTTCGGCC TCCTCCGGCT GTGCTCAGGG GTGTGGGGTA CGGATACAGA GGAGCGGCTG 360 GTGGAGCATC TCCTGGATCC TTCCCCCTAC AACAAGCTTA TCCCCCCACC CACCAATCGC 420 TCTGAGCTGG TGACAGTACA GCTTATGGTG TCACTGGCCC AGCTCATCAG TGTGCATGAG 480 CGGGAGCAGA TCATGACCAC CAATGTCTGG CTGACCCAGG AGTGGGAAGA TTATCGCCTC 540 ACCTGCAAGC CTCAAGAGTT TGACAACATG AAGAAAGTTC GGCTCCCTTC CAAACACATC 600 TCGCTCCCAG ATGTGGTCCT GTACAACAAT GCTCACGCCA TGTACGAGGT GTCCTTCTAT 660 TCCAATCCCG TGCTCTCCTA TGATGGCAGC ATCTTCTGGC TGCCGCCTGC CATCTACAAG 720 AGCCCATCCA AGATTGAAGT AAAGCACTTC CCATTTGACC AGCACAACTG CACCATGAAG 780 TTCCCTTCCT CGACCTACGA CCGCACAGAG ATCGACTTCG TCCTGAAGAG TCACCTGCCC 840 AGCCTGCACC ACTTCACACC TAGTCCTGAG TCGGACATCG TGGCGCTGCC CCGCCGGCGC 900 AACCACAACC CCGACCACTC TACGTACGTG GACATCACGT ATCACTTCAT CATTCGCCGC 960 AAGCCCCTCT TCTACACCAT CAACCTCATC ATCCCCTGTG TGCTCATCAC CTCCCTAGCC 1020 ATCCTTCTCT TCTACCTGCC ATCCCACTGT CGCGAGAACA TGACCTTCTC CATCTCAGTC 1080 CTCCTGGCGC TCACGGTCTT CCTGCTGCTC ATCTCCAAGA TCCTGCCTCC CACCTCCCTC 1140 GACGTGCCGC TCGTCGGCAA GTACCTCATG TTCACCATGG TGCTTGTCAC CTTCTCCATC 1200 GTCACCAGCG TGTGCGTGCT CAACGTGCAC CACCGCTCGC CCAGCACGCA CACCATGGCG 1260 CCCTGGGTGA AGGTCGTCTT CCTGGACAAG CTGCCCGCGC TGCTCTTCAT GCAGCAGGCA 1320 CGCCATCATT GCGCCCGTCA GCGCCTGCGC CTGCGGCGAC GCCAGCGTCA GCGCGAGGGC 1380 GCTGGAGCCC TCTTCTTCCG CGAAGCCCCA GGGGCCGACT CCTGCACGTG CTTCGTCAAC 1440 CGCGCGTCGG TGCAGGGGTT GGCCGGGGCC TTCGGGGCTG AGCCTGCACC AGTGGCGGGC 1500 CCCCCCCGCT CAGGGGAGCC GTGTGGCTGT GGCCTCCGGG AGGCGGTGCA CGGCGTGCGC 1560 TTCATCGCAG ACCACATGCG GAGCGAGGAC GATGACCAGA GCGTGAGTGA GGACTGGAAG 1620 TACGTCGCCA TGCTGATCGA CCGCCTCTTC GTCTGGATCT TTGTCTTTGT CTCTGTCTTT 1680 GGCACCATCG GCATGTTCCT GCAGCCTCTC TTCCAGAACT ACACCACCAC CACCTTCCTC 1740 CACTCAGACC ACTCAGCCCC CAGCTCCAAG TGAGGCCCTT CCTCATCTCC ATGCTCTTTC 1800 ACCCTGCCAC CCTCTGCTGC ACAGTAGTGT TGGGTGGAGG ATGGACGAGT GAGCTACCAG 1860 GAAGAGGGGC GCTGCCCCCA CAGATCCATC CTTTTGCTTC ATGTGGAGTC CCTCCTCCCC 1920 CACGCCTCCA TCCACACACA GCAGCTCCAA CCTGGAGGCT GGACCAACTG CTTTGTTTTG 1980 GCTGCTCTCC ATCTCTTGTA CCAGCCCAGG CAATAGTGTT GAGGAGGGGA GCAAGGCTGC 2040 TAAGTGGAAG ACAGAGATGG CAGAGCCATC CACCCTGAGG AGTGAGGGGC AAGGGGCCAG 2100 GAAGGGGACA GGATTGTCTG CTGCCTGGAA GTCATGGGAG AAGAGGGGTA TAGGACAAGG 2160 GGTGGAAGGG CAGGAGCTCA CACCGCACCG GGCTGGCCTG ACACAATGGT AGCTCTCAAG 2220 GGAGGCCAAG AGAGAGGCCT GGGTGTGACC TGACACCTGC CCCTGCTTGA GTCGACAGCA 2280 GCTCCACTGG GTGGGCCCCA CAGTGGTCAG CGATTCCTGC CAAGTAGCGT TTAGCCGGGC 2340 CCCATGGTCA CAGACCCCTG GGGGAGGCTT CCAGCTCAGT CCCACAGCCC CTTGCTTCTA 2400 AGGGATCCAG AGACCTGCTC CACATCCTCT TTCCCCACTG AAGAATTC 2448 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 502 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION:SEQ ID NO:10: Met Ala Arg Arg Cys Gly Pro Val Ala Leu Leu Leu Cly Phe Gly Leu 1 5 10 15 Leu Arg Leu Cys Ser Gly Val Trp Cly Thr Asp Thr Glu Giu Arg Leu 20 25 30 Val Glu His Leu Leu Asp Pro Ser Arg Tyr Asn Lys Leu Ile Arg Pro 35 40 45 Ala Thr Asn Gly Ser Glu Leu Val Thr Val Gin Leu Met Val Ser Leu 50 55 60 Ala Gin Leu Ile Ser Val His Glu Arg Clu Gln Ile Met Thr Thr Asn 65 70 75 80 Val Trp Leu Thr Gln Glu Trp Giu Asp Tyr Arg Leu Thr Trp Lys Pro 85 90 95 Glu Ciu Phe Asp Asn Met Lys Lys Val Arg Leu Pro Ser Lys His Ile 100 105 110 Trp Leu Pro Asp Val Val Leu Tyr Asn Asn Ala Asp Cly Met Tyr Giu 115 120 125 Val Ser Phe Tyr Ser Asn Ala Val Val Ser Tyr Asp Gly Ser lie Phe 130 135 140 Trp Leu Pro Pro Ala Ile Tyr Lys Ser Ala Cys Lys Ile Giu Val Lys 145 150 155 160 His Phe Pro Phe Asp Gln Gin Asn Cys Thr Met Lys Phe Arg Ser Trp 165 170 175 Thr Tyr Asp Arg Thr Glu Ile Asp Leu Val Leu Lys Ser Glu Val 180 185 190 Ser Leu Asp Asp Phe Thr Pro Ser Gly Clu Trp Asp lie Val Ala Leu 195 200 205 Pro Cly Arg Arg Asn Clu Asn Pro Asp Asp Ser Thr Tyr Val Asp lie 210 215 220 Thr Tyr Asp Phe Ile Ile Arg Arg Lys Pro Leu Phe Tyr Thr Ile Asn 225 230 235 240 Leu Ile Ile Pro Cys Val Leu Ile Thr Ser Leu Ala Ile Leu Val Phe 245 250 255 Tyr Leu Pro Ser Asp Cys Cly Ciu Lys Met Thr Leu Cys Ile Ser Val 260 265 270 Leu Leu Ala Leu Thr Val Phe Leu Leu Leu Ile Ser Lys Ile Val Pro 275 280 285 Pro Thr Ser Leu Asp Val Pro Leu Val Gly Lys Tyr Leu Met Phe Thr 290 295 300 Met Val Leu Val Thr Phe Ser Ile Val Thr Ser Val Cys Val Leu Asn 305 310 315 320 Val His His Arg Ser Pro Thr Thr His Thr Met Ala Pro Trp Val Lys 325 330 335 Val Val Phe Leu Glu Lys Leu Pro Ala Leu Leu Phe Met Gin Gin Pro 340 345 350 Arg His His Cys Ala Arg Gin Arg Leu Arg Leu Arg Arg Arg Gin Arg 355 360 365 Glu Arg Glu Gly Ala Gly Ala Leu Phe Phe Arg Glu Ala Pro Cly Ala 370 375 380 Asp Ser Cys Thr Cys Phe Val Asn Arg Ala Ser Val Gin Gly Leu Ala 385 390 395 400 Cly Ala Phe Gly Ala Giu Pro Ala Pro Val Ala Gly Pro Gly Arg Ser 405 410 415 Cly Giu Pro Cys Gly Cys Gly Leu Arg Giu Ala Val Asp Gly Val Arg 420 425 430 Phe Ile Ala Asp His Met Arg Ser Ciu Asp Asp Asp Gln Ser Val Ser 435 440 445 Clu Asp Trp Lys Tyr Val Ala Met Val Ile Asp Arg Leu Phe Leu Trp 450 455 460 Ile Phe Val Phe Val Cys Val Phe Gly Thr Ile Gly Met Phe Leu Gin 465 470 475 480 Pro Leu Phe Gln Asn Tyr Thr Thr Thr Thr Phe Leu His Ser Asp His 485 490 495 Ser Ala Pro Ser Ser Lys 500 (2) INFORMATION FOR SEQ ID NO.ll: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1915 base pairs (8) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 87..1583 (D) OTHER INFORMATION: /product- "BETA-4 SUBUNIT" (xi) SEQUENCE DESCRIPTION:SEQ ID NO:11: CCGGCGCTCA CTCGAGCGCG CGGCTCACGG GTGCCCTGTG ACCCCACAGC GGAGCTGGCG 60 CCGGCTGCCA CCCCCCCCCC CCGGCCATGA GGCGCGCGCC TTCCCTGGTC CTTTTCTTCC 120 TGGTCGCCCT TTGCGGGCGC GGGAACTGCC GCGTGGCCAA TGCGGAGGAA AAGCTGATGG 180 ACGACCTTCT GAACAAAACC CGTTACAATA ACCTGATCCG CCCACCCACC ACCTCCTCAC 240 AGCTGATCTC CATCAAGGTG CAGCTCTCCC TCCCCCACCT TATCAGCGTG AATGAGCGAG 300 ACCACATCAT GACCACCAAT CTCTGGCTGA AACAGCAATG GACTGATTAC CCCCTGACCT 360 GGAACAGCTC CCGCTACGAG GGTGTGAACA TCCTGAGGAT CCCTGCAAAC CGCATCTGGT 420 TCCCTCACAT CGTGCTTTAC AACAACGGCG ACCGGACCTA TGAGGTGTCT GTCTACACCA 480 ACTTCATAGT CCCCTCCAAC GGCAGCGTCC TGTGGCTGCC CCCTCCCATC TACAAGAGCG 540 CCTGCAAGAT TGAGGTGAAG TACTTTCCCT TCCACCAGCA GAACTGCACG CTCAACTTCC 600 GCTCCTGCAC CTATGACCAC ACGGAGATAG ACATGGTCCT CATGACCCCC ACACCCAGCA 660 TGGATGACTT TACTCCCACT GCTGAGTGGC ACATACTGCC CCTCCCACGG AGAACGACAG 720 TGAACCCACA AGACCCCAGC TACGTGGACG TGACTTACGA CTTCATCATC AAGCGCAAGC 780 CTCTCTTCTA CACCATCAAC CTCATCATCC CCTCCGTCCT CACCACCTTG CTCCCCATCC 840 TCGTCTTCTA CCTGCCATCC GACTGCGGCG AGAAGATGAC ACTGTGCATC TCAGTGCTGC 900 TGGCACTGAC ATTCTTCCTG CTGCTCATCT CCAACATCGT CCCACCCACC TCCCTCCATC 960 TGCCTCTCAT CGGCAAGTAC CTCATGTTCA CCATGGTGCT GGTCACCTTC TCCATCGTCA 1020 CCAGCGTCTC TGTGCTCAAT GTGCACCACC GCTCGCCCAG CACCCACACC ATGGCACCCT 1080 GGGTCAACCG CTCCTTCCTC CACAAGCTCC CTACCTTCCT CTTCATCAAG CGCCCTGCCC 1140 CCGACAGCAG CCCGGCCAGA GCCTTCCCGC CCAGCAAGTC ATGCGTGACC AAGGGGGAGG 1200 CCACCGCCAC CTCCACCAGC CCCTCCAACT TCTATCGGAA CTCCATCTAC TTTGTGAACC 1260 CCCCCTCTGC AGCTTCCAAG TCTCCAGCCC GCTCTACCCC GGTGGCTATC GCCAGCGATT 1320 TCTCGCTGCG GTCCTCTGGG AGGTTCCGAC AGGATGTGCA GGAGCCATTA CAAGGTCTCA 1380 GCTTCATCGC CCAGCACATG AAGAATGACG ATGAAGACCA GAGTGTCGTT GAGGACTGGA 1440 AGTACGTGGC TATGGTGGTG GACCGGCTGT TCCTGTGGGT GTTCATGTTT GTGTGCGTCC 1500 TGGGCACTGT GGGGCTCTTC CTGCCGCCCC TCTTCCAGAC CCATGCAGCT TCTGAGGGGC 1560 CCTACGCTGC CCAGCGTGAC TGAGGGCCCC CTGGGTTGTG GGGTGAGAGG ATGTGAGTGG 1620 CCGGGTGGGC ACTTTGCTGC TTCTTTCTGG GTTGTGGGCG ATGAGGCCCT AAGTAAATAT 1680 GTGAGCATTG GCCATCAACC CCATCAAACC AGCCACAGCC GTGGAACAGG CAAGGATGGG 1740 GGCCTGGCCT GTCCTCTCTG AATGCCTTCG AGGGATCCCA GGAAGCCCCA GTAGGAGGGA 1800 CCTTCAGACA GTTCAATTCT GCCCTGTCTT CCTTCCCTCC ACCGGGCAAT GGGGATAAAG 1860 ATCACTTCCT AGCAGCACCT ACTATGCTTC ACGCATCCTC CCGGCCTGCC TCTCC 1915 (2) INFORMATiON FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 498 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Met Arg Arg Ala Pro Ser Leu Val Leu Phe Phe Leu Val Ala Leu Cys 1 5 10 15 Gly Arg Cly Asn Cys Arg Val Ala Asn Ala Glu Ciu Lys Leu Met Asp 20 25 30 Asp Leu Leu Asn Lys Thr Arg Tyr Asn Asn Leu lle Arg Pro Ala Thr 35 40 45 Ser Ser Ser Gln Leu Ile Ser Ile Lys Leu Gln Leu Ser Leu Ala Gin 50 55 60 Leu Ile Ser Val Asn C1u Arg Glu Gin Ile Met Thr Thr Asn Val Trp 65 70 75 80 Leu Lys Gin Glu Trp Thr Asp Tyr Arg Leu Thr Trp Asn Ser Ser Arg 85 90 95 Tyr Giu Gly Val Asn Ile Leu Arg Ile Pro Ala Lys Arg Ile Trp Leu 100 105 110 Pro Asp Ile Val Leu Tyr Asn Asn Ala Asp Gly Thr Tyr Giu Val Ser 115 120 125 Val Tyr Thr Asn Leu lie Val Arg Ser Asn Gly Ser Val Leu Trp Leu 130 135 140 Pro Pro Ala Ile Tyr Lys Ser Ala Cys Lys Ile Glu Val Lys Tyr Phe 145 150 155 160 Pro Phe Asp Gln Gln Asn Cys Thr Leu Lys Phe Arg Ser Trp Thr Tyr 165 170 175 Asp His Thr Glu Ile Asp Met Val Leu Met Thr Pro Thr Ala Ser Met 180 185 190 Asp Asp Phe Thr Pro Ser Gly Ciu Trp Asp Ile Val Ala Leu Pro Gly 195 200 205 Arg Arg Thr Val Asn Pro Gin Asp Pro Ser Tyr Val Asp Val Thr Tyr 210 215 220 Asp Phe lie Ile Lys Arg Lys Pro Leu Phe Tyr Thr Ile Asn Leu Ile 225 230 235 240 lie Pro Cys Val Leu Thr Thr Leu Leu Ala lie Leu Val Phe Tyr Leu 245 250 255 Pro Ser Asp Cys Gly Clu Lys Met Thr Leu Cys Ile Ser Val Leu Leu 260 265 270 Ala Leu Thr Phe Phe Leu Leu Leu Ile Ser Lys Ile Val Pro Pro Thr 275 280 285 Ser Leu Asp Val Pro Leu Ile Gly Lys Tyr Leu Met Phe Thr Met Val 290 295 300 Leu Val Thr Phe Ser Ile Val Thr Ser Val Cys Val Leu Asn Val His 305 310 315 320 His Arg Ser Pro Ser Thr His Thr Met Ala Pro Trp Val Lys Arg Cys 325 330 335 Phe Leu His Lys Leu Pro Thr Phe Leu Phe Met Lys Arg Pro Gly Pro 340 345 350 Asp Ser Ser Pro Ala Arg Ala Phe Pro Pro Ser Lys Ser Cys Val Thr 355 360 365 Lys Pro Glu Ala Thr Ala Thr Ser Thr Ser Pro Ser Asn Phe Tyr Gly 370 375 380 Asn Ser Met Tyr Phe Val Asn Pro Ala Ser Ala Ala Ser Lys Ser Pro 385 390 395 400 Ala Gly Ser Thr Pro Val Ala Ile Pro Arg Asp Phe Trp Leu Arg Ser 405 410 415 Ser Gly Arg Phe Arg Cln Asp Val Gln Glu Ala Leu Glu Cly Val Ser 420 425 430 Phe Ile Ala Gin His Met Lys Asn Asp Asp Glu Asp Gin Ser Val Val 435 440 445 Glu Asp Trp Lys Tyr Val Ala Met Val Val Asp Arg Leu Phe Leu Trp 450 455 460 Val Phe Met Phe Val Cys Val Leu Gly Thr Val Gly Leu Phe Leu Pro 465 470 475 480 Pro Leu Phe Gln Thr His Ala Ala Ser Giu Cly Pro Tyr Ala Ala Gin 485 490 495 Arg Asp

Claims (23)

CLAIMS:

1. Isolated DNA comprising nucleotides encoding a 4 subunit of a human neuronal nicotinic acetylcholine receptor.

2. DNA according to claim 1 wherein the nucleotides of said DNA encode the amino acid sequence set forth in SEQ ID No:12.

3. DNA according to claim 1 wherein the nucleotides of said DNA hybridize under high stringency conditions to substantially the entire coding sequences set forth in SEQ ID Neo:11.

4. DNA according to claim 1 wherein the nucleotides of said DNA hybridize under high stringency conditions to nucleotide 87 to about nucleotide 155 set forth in SEQ ID Neo:11.

5. DNA according to claim 1 wherein the nucleotides of said DNA hybridize under high stringency conditions to nucleotide 87 to about nucleotide 227 set forth in SEQ ID No:l1.

6. DNA according to claim 1 wherein the nucleotides of said DNA have the sequence of nucleotides 87-1583 set forth in SEQ ID No: 11.

7. DNA according to claim 1 comprising the sequence of nucleotides set forth in SEQ ID No:ll.

8. Cells transformed with at least one DNA according to claim 1, wherein said cells are bacterial cells, eukaryotic cells or amphibian ocytes.

9. Cells according to claim 8, further transformed with at least one DNA encoding an a subunit of a human neuronal nicotinic acetylcholine receptor with the proviso that said a subunit is not an a4 or an a7 subunit.

10. Cells according to claim 9 further characterized as being capable of expressing voltage dependent calcium channels.

11. Cells according to claim 9 wherein said a subunit is selected from a1, a2, a3 or a5.

12. Cells according to claim 9 transformed with DNA encoding human a3 and human ss4 subunits.

13. Cells according to claim 8 wherein said cells express functional neuronal nicotinic acetylcholine receptors that contain one or more subunits encoded by said DNA.

14. A method of screening compounds to identify compounds which modulate the activity of human neuronal nicotinic acetylcholine receptors, said method comprising determining the effect of a compound on the neuronal nicotinic acetylcholine receptor activity in test cells according to claim 6, compared to the effect on control cells or to the neuronal nicotinic acetylcholine receptor activity of the cells in the absence of the compound, wherein control cells are substantially identical to the test cells, but control cells do not express nicotinic acetylcholine receptors.

15. Recombinant human neuronal nicotinic acetylcholine receptor pus subunit.

16. A recombinant human neuronal nicotinic acetylcholine receptor comprising the subunit of claim 15.

17. Human neuronal nicotinic acetylcholine receptor according to claim 16, further comprising at least one human neuronal nicotinic acetylcholine receptor alpha subunit with the proviso that said alpha subunit is not an 4 or a7 subunit.

18. A method for identifying functional neuronal nicotinic acetylcholine receptor subunits and combinations thereof, said method comprising: (a) introducing into eukaryotic cells at least one DNA according to claim 1, or RNA complementary thereto, and DNA encoding at least one alpha subunit of a neuronal nicotinic acetylcholine receptor, or RNA complementary thereto, with the proviso that said alpha subunit is not an a4 or an a7 subunit; and (b) assaying for neuronal nicotinic acetylcholine receptor activity in cells of step (a), wherein the activity is mediated by a receptor containing one or more of the subunits encoded by said introduced DNA.

19. Isolated mRNA encoded by the DNA of claim 1.

20. Cells transformed with mRNA according to claim 19.

21. Cells according to claim 20 further transformed with mRNA encoding an alpha subunit of a human neuronal nicotinic acetylcholine receptor with the proviso that said alpha subunit is not an 4 or an a7 subunit.

22. An antibody generated against the protein of claim 15 or an immunogenic portion thereof.

23. A probe comprising at least 14 contiguous nucleotides, or the complement thereof, as set forth in the sequence of nucleotides 87-155 of SEQ ID No:ll.